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resumo 
 
 
As doenças de sobrecarga lisossomal (DSLs) constituem um grupo de 
distúrbios metabólicos raros maioritariamente causados por mutações em 
hidrolases lisossomais, que conduzem à acumulação anormal de diferentes 
substratos macromoleculares no interior do lisossoma. Este trabalho é focado 
nas mucopolissacaridoses (MPSs), um grupo de DSLs resultantes da atividade 
deficiente de enzimas envolvidas no catabolismo dos glicosaminoglicanos. A 
MPS II é caraterizada pela perda de atividade da enzima iduronato-2-sulfatase, 
levando ao armazenamento intralisossomal de sulfato de dermatano e sulfato 
de heparano. A MPS VI é definida pela acumulação de sulfato de dermatano 
dentro do lisossoma, devido a uma deficiência na atividade enzimática de 
arilsulfatase B. O lisossoma é um compartimento celular importante para o 
funcionamento normal do sistema imunitário. Em diversos modelos de DSLs, 
foram anteriormente descritas alterações nas células do sistema imunitário. Os 
principais objetivos do presente trabalho eram: (i) estudar as várias populações 
leucocitárias – incluindo células T e seus subconjuntos, células natural killer 
(NK), células B e suas subpopulações, e monócitos – no sangue periférico de 
doentes com MPS II e MPS VI; (ii) produzir linhas de células B transformadas 
pelo vírus Epstein–Barr (EBV) destes pacientes, assim como avaliar a eficácia 
na sua produção e determinar o seu fenótipo. A caraterização do sistema 
imunitário nas doenças MPS II e MPS VI revelou um decréscimo significativo 
na frequência de células NK e monócitos em doentes com MPS VI, mas não 
em doentes com MPS II, em comparação com indivíduos controle. Em 
contraste, não foram identificadas alterações na percentagem de células T, 
células natural killer T invariantes (iNKT) e células B nos grupos de doentes 
com MPS II e MPS VI, comparando com o grupo controlo. A análise detalhada 
do estado de memória de células T auxiliares e células T citotóxicas revelou 
desequilíbrios nos fenótipos naïve e de memória em ambos os compartimentos 
de células T em doentes com MPS VI, mas não em doentes com MPS II, em 
comparação com indivíduos controle. As linhas de células B transformadas 
pelo EBV foram produzidas com sucesso nos dois grupos de doentes com 
MPS, mas a eficácia na sua produção foi superior no caso dos doentes com 
MPS VI, comparando com os indivíduos controle e doentes com MPS II. O 
fenótipo predominante das linhas de células B transformadas pelo EBV era 
similar entre ambos os grupos de doentes com MPS e o grupo controlo, o qual 
foi avaliado como sendo correspondente à subpopulação de células B de 
memória duplamente negativas. Em conclusão, este trabalho permitiu 
caraterizar melhor o sistema imunitário nestas duas doenças raras. 
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abstract 
 
Lysosomal storage diseases (LSDs) constitute a group of rare metabolic 
disorders mostly caused by mutations in lysosomal hydrolases, which conduce 
to abnormal accumulation of different macromolecular substrates inside the 
lysosome. This work is focused on the mucopolysaccharidoses (MPSs), a 
group of LSDs arising from the deficient activity of enzymes involved in the 
catabolism of glycosaminoglycans. The MPS II is characterized by loss of 
activity of the enzyme iduronate-2-sulfatase, leading to the intralysosomal 
storage of dermatan sulfate and heparan sulfate. The MPS VI is defined by the 
accumulation of dermatan sulfate within the lysosome, owing to a deficiency in 
the enzymatic activity of arylsulfatase B. The lysosome is an important cellular 
compartment for the normal functioning of the immune system. In several 
models of LSDs, alterations in the immune system cells were previously 
described. The main aims of the present work were: (i) to study the various 
leukocyte populations – including T cells and their subsets, natural killer (NK) 
cells, B cells and their subpopulations, and monocytes – in the peripheral blood 
of MPS II and MPS VI patients; (ii) to produce Epstein–Barr virus (EBV)-           
-transformed B cell lines from these patients, as well as to evaluate the efficacy 
in their generation and determine their phenotype. The characterization of the 
immune system in MPS II and MPS VI diseases revealed a significant 
decrease in the frequency of NK cells and monocytes in MPS VI patients, but 
not in MPS II patients, in comparison with control subjects. In contrast, no 
alterations were identified in the percentage of T cells, invariant natural killer T 
(iNKT) cells, and B cells in the groups of MPS II and MPS VI patients 
comparing with the control group. The detailed analysis of the memory state of 
helper T cells and cytotoxic T cells revealed imbalances in the naïve and 
memory phenotypes in both T cell compartments in MPS VI patients, but not in 
MPS II patients, as compared with control subjects. The EBV-transformed B 
cell lines were successfully produced in the two MPS patient groups, but the 
efficacy in their generation was higher in the case of MPS VI patients when 
comparing with control subjects and MPS II patients. The predominant 
phenotype of EBV-transformed B cell lines was similar between both groups of 
MPS patients and the control group, which was assessed as corresponding to 
the double-negative memory B cell subpopulation. In conclusion, this work 
allowed to better characterize the immune system in these two rare diseases. 
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1. INTRODUCTION 
 
1.1. Lysosomal storage diseases 
 
The lysosome, an organelle containing more than sixty types of acid hydrolases, is the 
major intracellular site for enzymatic degradation of most macromolecules [1–7]. By fusing with 
late endosomes/phagosomes or autophagosomes, macromolecular substrates are delivered to the 
lysosome to be digested by soluble lysosomal hydrolytic enzymes [1–6]. The resulting breakdown 
products are transported back to the cytosol by membrane-bound lysosomal transporter proteins 
or via vesicular membrane trafficking [1,3,4,6]. Hence, lysosomal catabolites become available for 
being subsequently used in energy homeostasis or reutilized in new biosynthetic processes by 
other cell organelles [1,4]. 
Additional functions of the lysosome include antigen presentation, innate immunity, 
phagocytosis, autophagy, signal transduction, receptor recycling and regulation, cell membrane 
repair, tissue remodeling, neurotransmission, and apoptosis [2,4,7]. 
 
Lysosomal storage diseases (LSDs) constitute a heterogeneous group comprising over 
fifty rare, genetically distinct metabolic disorders, which arise mostly from recessively inherited, 
loss-of-function mutations that impair the intralysosomal catabolic pathways [1–7]. The genetic 
alterations typically affect a soluble lysosomal hydrolase, but mutations in genes coding a non-          
-enzymatic lysosomal protein or a non-lysosomal protein implicated in the biogenesis or vesicular 
trafficking of lysosomal proteins may also be associated with LSD phenotypes [1–4,6,7]. In 
consequence of the deficiency of a protein critical for lysosome function or regulation, the 
intralysosomal accumulation of non-degraded macromolecules or monomeric catabolic products 
progressively occurs, especially in cells, tissues, and organs where substrate turnover is high [1–4, 
6,7]. Owing to this primary storage leading to enlarged dysfunctional lysosomes, many other 
enzymatic processes are eventually inhibited, which results in the accumulation of secondary 
undigested compounds [2,3,6]. Thus, not only the lysosomal activity is impaired but also the 
functions of other organelles (e.g. Golgi complex, mitochondria, endoplasmic reticulum) may be 
compromised, causing a multisystemic dysfunction of numerous cell activities [2,3,6,7]. 
According to the nature of the major materials that accumulate within the lysosome, LSDs 
are typically categorized in mucopolysaccharidoses (MPSs), sphingolipidoses, other lipidoses, 
glycoproteinoses, and glycogenosis [4,5]. Moreover, some LSDs are grouped depending on the 
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lysosomal protein defects, being classified as multiple lysosomal enzyme deficiencies and 
lysosomal transport deficiencies [5]. 
Although being considered individually rare, the overall combined prevalence of LSDs is 
around 12.5 per 100,000 live births [3], but it may be as high as 20 per 100,000 live births if 
undiagnosed or misdiagnosed cases are accounted for [6]. Epidemiological studies conducted in 
different countries reported a collective prevalence of LSDs of approximately 8 in British 
Columbia [8], 12.08 in Italy [9], 12.25 in the Czech Republic [10], 12.99 in Australia [11], and 14 
per 100,000 live births in The Netherlands [12]. Considering the Portuguese population, this 
group of inborn errors of metabolism occurs with a higher combined prevalence, which is 
estimated to be 25 per 100,000 live births, with the sphingolipidoses as the most prevalent 
subclass, followed by the MPSs [13]. 
 
Within the LSDs, the subgroup of MPSs is the focus of this thesis, which is discussed 
hereinafter. 
 
 
1.1.1. Mucopolysaccharidoses 
 
MPSs constitute a family of rare, inherited metabolic disorders resulting from a deficiency 
in the activity of specific lysosomal enzymes implicated in the catabolism of glycosaminoglycans 
(GAGs) [4,7,14–19]. The global prevalence of MPSs is around 1.9 in British Columbia [8], 2.4 in 
Italy [9], 3.7 in the Czech Republic [10], 4.4 in Australia [11], and 4.5 per 100,000 live births in 
The Netherlands [12]. More particularly, the prevalence of this type of LSD in Portugal is 
approximately 4.8 per 100,000 live births [13]. 
GAGs are unbranched polymeric chains of carbohydrates consisting of specific repeating 
disaccharide units, being divided in four main groups: (i) dermatan sulfate (DS) and chondroitin 
sulfate (CS); (ii) hyaluronan; (iii) heparan sulfate (HS); and (iv) keratan sulfate (KS) [4,7,14,15, 
17–20]. With the exception of hyaluronan, all other GAGs occur naturally as components of 
proteoglycans by binding to secreted or cell surface-attached glycoproteins [7,14,15,18–20]. 
Proteoglycans, along with hyaluronan, are important constituents of many extracellular matrices, 
participating in cell adhesion and neuritogenesis (e.g. DS, CS), activation of growth factors and 
composition of cellular membranes (e.g. HS), cell motility and neuronal regeneration (e.g. KS), as 
well as tissue hydration and resistance to compression (e.g. hyaluronan) [7,17,18,20]. During 
3 
 
proteolytic removal of the core protein, proteoglycans are metabolized into DS, CS, HS, or KS 
outside the cell [14,15]. Along with hyaluronan, these GAGs are delivered by endocytosis and 
autophagy to the lysosome to undergo intracellular digestion, a process involving five sulfatases, 
four exoglycosidases, one non-hydrolytic transferase, and one endoglycosidase [14,15,17,18]. 
Any deficiency of one of these lysosomal enzymes conduces to blockade of the stepwise 
degradation of DS, CS, HS, KS, or hyaluronan and may affect one or several GAG breakdown 
pathways simultaneously [14,15,17,18]. Because presentation of these substrates to cells for 
intralysosomal catabolism continues to occur normally, there is a persistent accumulation of 
undigested or partially degraded GAGs inside lysosomes and in the extracellular matrix of a 
variety of tissues, leading to alteration of cell homeostasis [7,14–19]. In addition, MPSs are 
biochemically defined by an increase of GAG fragments in urine, blood, and/or cerebrospinal fluid 
of affected patients [14–19]. 
 
As GAGs are a crucial structural element of the extracellular matrix of all animal tissues, 
the impairment of their catabolism potentiates a diversity of alterations that extend to virtually all 
organ systems [7,15,16,19]. The various MPS disorders share a multisystemic clinical picture that 
typically consists of dysostosis multiplex, growth retardation, abnormal facies, and organomegaly, 
as well as variable cardiovascular, respiratory, auditory, and visual involvement, accompanied by 
neurocognitive dysfunction in some cases [4,7,14–17,19]. Even though MPS patients may have a 
normal appearance at birth, soon their childhood is marked by the onset of symptomatic disease, 
characterized by a chronic, progressive course and different degrees of severity [14–17]. 
 
Early and accurate diagnosis is of paramount importance due to the multisystemic and 
progressive nature of MPSs, and also because it can frankly improve treatment outcomes in those 
types for which enzyme replacement therapy (ERT) or hematopoietic stem cell transplantation 
(HSCT) are currently available [16,19]. Nonetheless, given that clinical symptoms are highly 
heterogeneous, diagnosis is often difficult to perform and inevitably delayed, which may 
potentiate the occurrence of irreversible organ damage [16,19]. 
 
The general characterization of the MPSs, including the deficient lysosomal enzyme, the 
genetic inheritance and mutated gene locus, as well as the major GAG storage materials 
accumulated intralysosomally, is summarized in Table 1.1. 
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Table 1.1. General classification of MPS disorders [4,14–16] 
Disease Enzymatic deficiency 
Genetic heritage 
(gene locus) 
Increased 
GAGs 
MPS I 
α-L-iduronidase 
 
DS, HS 
Hurler Autosomal recessive 
Hurler-Scheie (IDUA: 4p16.3) 
Scheie  
MPS II 
Iduronate-2-sulfatase 
X-linked recessive 
DS, HS 
(Hunter) (IDS: Xq28) 
MPS III  Autosomal recessive 
HS 
Sanfilippo A Heparan-N-sulfatase (SGSH: 17q25.3) 
Sanfilippo B α-N-acetyl-glucosaminidase (NAGLU: 17q21) 
Sanfilippo C 
Acetyl-CoA:α-glucosaminide 
N-acetyltransferase 
(HGSNAT: 8p11.21) 
Sanfilippo D N-acetylglucosamine-6-sulfatase (GNS: 12q14) 
MPS IV  Autosomal recessive  
Morquio A Galactose-6-sulfatase (GALNS: 16q24.3) KS, CS 
Morquio B β-galactosidase (GLB1: 3p22.3) KS 
MPS VI 
Arylsulfatase B 
Autosomal recessive 
DS 
(Maroteaux-Lamy) (ARSB: 5q13–q14) 
MPS VII 
β-glucuronidase 
Autosomal recessive 
DS, CS, HS 
(Sly) (GUSB: 7q21.11) 
MPS IX 
Hyaluronidase 1 
Autosomal recessive 
Hyaluronan 
(Natowicz) (HYAL1: 3p21.31) 
 
 
This thesis specifically approaches the MPS II and MPS VI diseases, which are described 
with more detail henceforth. 
 
 
1.1.1.1. Mucopolysaccharidosis type II 
 
MPS II, or Hunter syndrome, is a rare LSD arising from reduced or absent activity of the 
lysosomal hydrolase iduronate-2-sulfatase (IDS) [14–16,18,21–24]. This recessive disorder differs 
from all other MPSs by the fact that presents an X-linked genetic heritage, occurring almost 
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exclusively in males; even so, rare female patients have also been reported, which can be due to a 
non-random X-chromosome inactivation in carrier females [14–16,18,21–24]. The estimated 
prevalence of MPS II is approximately 1.2 in Italy [9], 0.43 in the Czech Republic [10], 0.74 in 
Australia [11], and 0.67 per 100,000 live births in The Netherlands [12]. In the Portuguese 
population, this disease presents a prevalence of around 1.09 per 100,000 live births [13]. 
 
Molecular basis 
MPS II occurs as a result of partially or completely defective activity of the enzyme IDS, a 
lysosomal sulfatase that is codified by the IDS gene positioned at the locus Xq28, which spans 
about 24kb and contains nine exons [14,15,21–23,25]. 
Within the lysosome, IDS is responsible for the correct degradation of both DS and HS by 
removing the sulfate group from the 2- position of L-iduronic acid residue situated at the non-        
-reducing terminus of these GAGs [14,15,22,23]. The breakdown pathways of DS and HS, including 
the specific enzymatic reactions blocked in MPS II, are represented in Figure 1.1. 
 
 
Figure 1.1. Deficiencies in GAG catabolism in MPS II disease. Adapted from [14]. Represented are 
the enzymatic reactions in the stepwise degradation pathways of DS (A) and HS (B) that are blocked in 
Hunter syndrome. 
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Numerous mutations can affect the IDS gene, namely small insertions (e.g. 1269insCC) 
and deletions (e.g. 383delAT), as well as missense (e.g. S71R), nonsense (e.g. Y234X), and altered 
splicing (e.g. 1122C→T) errors, many of which are private or non-recurrent mutations that 
together cause 75–80% of MPS II cases [14,21,22,25]. The remaining fifth of cases are due to gene 
rearrangements (e.g. recombination, followed by inversion, of the IDS gene with an IDS-like 
pseudogene) and large deletions (e.g. intragenic deletion of exons 4–7), which always result in a 
severe MPS II phenotype [14,21–23,25]. 
The diminution or lack of such enzymatic activity arising from mutations in the IDS gene 
leads to continuous storage of HS and DS, both inside cells and extracellularly, in nearly all cell 
types, in addition to causing the urinary excretion of excessive amounts of these two non-                
-degraded GAGs [14,15,22,23]. In some cases, the secondary accumulation of GM2 and GM3 
gangliosides occurs in the brains of affected individuals, owing to the inhibition of enzymes 
involved in ganglioside metabolism, elicited by primary intralysosomal storage of HS and DS [14]. 
 
Clinical presentation 
In MPS II, neurological and somatic involvement are usually present, in which multiple 
manifestations affect the brain and musculoskeletal, cardiovascular, and respiratory systems  
[14–16,21,24]. Although many severity degrees exist, two major clinical entities are recognized as 
the extremes of a continuum of multisystemic symptoms: severe and mild MPS II [14,15,22–24]. 
About two-thirds of patients exhibit the severe form of MPS II, defined by progressive 
neurodegeneration and cognitive dysfunction, as well as serious somatic impairment, culminating 
in reduced life expectancy [14–16,21–24]. Around 2–4 years of age, a series of clinical symptoms 
arise: mental retardation, dysostosis multiplex, short stature, facial dysmorphia, umbilical and 
inguinal hernias, chronic diarrhea, hepatosplenomegaly, recurrent otitis and gradual hearing loss, 
retinal dystrophy, and small ivory-colored papules (pebbling) in the skin – a pathognomonic 
feature – are common findings [14,16,21–24]. In early childhood, patients also experience several 
cardiologic and pulmonary complications, such as myocardial disease and repetitive respiratory 
infections [14,16,21,22]. The communicating hydrocephalus and increased intracranial pressure 
aggravate the already extensive neurological deterioration, leading to a late-stage with seizures 
and lack of mobility [14,16,21,22]. Natural death generally occurs at the age of 10–15 years old, as 
a result of obstructive airway disease combined with cardiac failure [14–16,21–24]. 
Patients with the milder phenotype of MPS II possess normal intelligence, with little to no 
cognitive impairment, as well as attenuated somatic involvement compatible with survival into 
adulthood [14–16,21–24]. First symptoms have a late onset, usually between 4 and 8 years of age, 
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with joint stiffness, hepatosplenomegaly, spinal cord compression with cervical myelopathy, 
carpal tunnel syndrome, and hearing deficiency as classical manifestations [14,16,22]. Mildly 
affected patients display several somatic abnormalities that are also present in individuals with 
severe MPS II, but which develop with a slower progression [14,16,22]. Natural death may occur 
prematurely in late-teenage years or in early adulthood secondary to chronic cardiorespiratory 
problems, but some patients live until their fifth or sixth decades of life [14,16,22–24]. 
The overall clinical symptoms typically expressed in MPS II are summed up in Table 1.2 
and the characteristic features of affected patients are shown in Figure 1.2. 
 
Table 1.2. Clinical symptoms characteristic of MPS II disease [14,16,21,22,24] 
Organ/system 
affected 
Clinical manifestations 
Nervous system 
Restricted to the severe phenotype 
– Developmental delay – Seizures 
– Behavioral changes: aggressiveness and hyperactivity 
Commonly present in both mild and severe phenotypes 
– Carpal tunnel syndrome – Spinal cord compression 
– Communicating hydrocephalus  
Musculoskeletal 
system 
– Short stature – Coarse facial features 
– Joint stiffness and contractures – Overall restricted mobility 
– Spine deformities – Hand and wrist deformities 
– Pelvic dysplasia – Short neck and limbs 
Cardiovascular 
system 
– Cardiac valve lesions – Coronary artery narrowing 
– Ventricular hypertrophy – Pulmonary hypertension 
Respiratory 
system 
– Repetitive upper respiratory tract infections 
– Obstructive sleep apnea – Thick nasal/tracheal secretions 
Gastrointestinal 
system 
– Hepatomegaly – Splenomegaly 
– Chronic diarrhea – Umbilical and inguinal hernias 
Visual system 
– Retinal dystrophy – Papilledema 
– Optic nerve atrophy  
Auditory system – Recurrent otitis – Gradual hearing loss 
Skin – Mongolian blue spots – Pebbling 
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Figure 1.2. Typical features of MPS II patients [24]. Evidence of short stature, joint stiffness 
(inability to raise arms above head), short neck [left], and coarse facies (enlarged head, large jowls, 
thickened lips, broad nose, and prominent supraorbital ridges) [right]. 
 
Diagnosis 
MPS II is usually suspected on the basis of clinical presentation, with patients exhibiting 
skeletal deformities, coarse facies, short stature, organomegaly, recurrent hearing infections, and 
thickened pebbled skin [24]. However, a suspicion based on clinical findings is not sufficient to 
diagnose MPS II, since it is phenotypically similar to other MPSs or even some other LSDs [24]. 
Quantitative and qualitative analyses of urinary GAGs are the first screening tests used to 
assess if a subject has a form of MPS, but elevated levels of total urinary GAGs, as well as the 
accumulation of DS and HS in urine, do not confirm a specific diagnosis of MPS II [23,24]. 
An enzyme assay performed on leukocytes, fibroblasts, plasma, or dried blood spots that 
reveals a deficiency of IDS activity is required for a definitive diagnosis [16,23,24]. The distinction 
between mild and severe MPS II has to be based on clinical symptoms, as IDS activity measured in 
vitro is equally deficient in both forms [14,15,23,24]. The evidence of the normal activity of other 
sulfatase is crucial, since low levels of IDS may also indicate multiple sulfatase deficiency [23,24]. 
Molecular genetic testing can be used to identify the pathologic mutation(s) that affect the 
IDS gene and also allows for genetic counselling and carrier testing to be offered to at-risk family 
members, as well as for identifying affected embryos in prenatal diagnosis [16,21,23,24]. 
 
Treatment 
Given the wide range of clinical manifestations present in MPS II, medical support (e.g. 
from orthopedic surgeons, pneumologists, neurologists, cardiologists) has been essential to 
manage individual symptom complications and improve patients’ quality of life [19,21,23,24]. 
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Until the recent past, HSCT was the only disease-specific therapeutic tool available for 
MPS II that allowed correcting the deficient IDS activity [21]. Although some somatic benefits 
were obtained in few cases, the results at neurological level were not equally promising; thus, 
such improvements did not exceed the high rate of morbidity and mortality associated to this 
procedure [16,18,19,21,23,24]. Because the same benefits are achieved through specific ERT and 
with fewer risks, HSCT has not shown promise as a therapy for MPS II [16,21,24]. 
ERT with idursulfase (Elaprase®, Shire Human Genetic Therapies Inc.) – a recombinant 
enzyme analogous to native human IDS – is the treatment of choice for MPS II since its approval in 
the European Union, in 2007 [18,21–24]. ERT can be applied to all symptomatic patients with 
confirmed diagnosis, being performed on a weekly basis through intravenous infusion of a dose of 
0.5mg/kg for 1–3 hours [21–24]. Providing the exogenous enzyme to IDS-deficient cells was 
shown to attenuate the progressive course of somatic involvement by reducing liver and spleen 
size, respiratory infections, facial coarseness, and urinary GAG excretion, as well as through the 
improvement in obstructive sleep apnea, joint mobility, and walking ability [18,19,21–24]. Still, as 
idursulfase does not cross the blood-brain barrier nor reaches the bone cells, ERT does not have 
neurocognitive benefit in severe MPS II patients neither corrects the bone disease [17–19,22–24]. 
New approaches for delivering the recombinant enzyme to the brain and bone structures 
are currently under study, such as ERT via intrathecal injections and gene therapy [17–19,23,24]. 
 
 
1.1.1.2. Mucopolysaccharidosis type VI 
 
MPS VI, or Maroteaux-Lamy syndrome, is a rare LSD caused by deficit of the enzymatic 
activity of arylsulfatase B (ARSB, or N-acetylgalactosamine-4-sulfatase) [14–16,18,21,26]. As with 
most MPSs, this genetic disease is transmitted in an autosomal recessive pattern, occurring with 
equal frequency in males and females [14–16,21,26]. The prevalence of MPS VI is around 0.05 in 
the Czech Republic [10], 0.43 in Australia [11], and 0.15 per 100,000 live births in The 
Netherlands [12]. In Portugal, its prevalence is estimated in 0.42 per 100,000 live births [13]. 
 
Molecular basis 
MPS VI is instigated by complete or partial loss of activity of the lysosomal sulfatase ARSB, 
which arises from mutations in the ARSB gene that is positioned at the locus 5q13–q14 and 
comprises 8 exons spread over 206kb [14,15,21,26,27]. 
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Functionally, ARSB promotes the degradation of DS inside the lysosome by catalyzing the 
removal of the C4 sulfate ester group from N-acetylgalactosamine 4-sulfate sugar residue at the 
non-reducing end of this GAG [14,15,26,27]. The breakdown pathway of DS, including the 
enzymatic reaction blocked in MPS VI, is represented in Figure 1.3. 
 
 
Figure 1.3. Deficiency in GAG catabolism in MPS VI disease. Adapted from [14]. Represented is the 
enzymatic reaction in the stepwise degradation pathway of DS (A) that is blocked in Maroteaux-Lamy 
syndrome. 
 
A large number of private mutations in the ARSB gene were reported with relative low 
frequency in single families, which comprise insertion (e.g. 1161insC), deletion (e.g. 427delG), 
missense (e.g. Y210C), nonsense (e.g. R160X), and splice junction errors (e.g. 1143–8T>G) [14,21, 
26,27]. This genetic heterogeneity may be a major contributing factor for the wide spectrum of 
clinical symptoms manifested by the affected individuals [27]. 
In consequence of the deficiency of such enzymatic activity determined by pathogenic 
mutations in the ARSB gene, MPS VI patients demonstrate an inability to efficiently degrade DS, 
resulting in the intralysosomal storage of this partially digested GAG material with subsequent 
cell and tissue injury, along with its excretion in urine [14,15,26,27]. 
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Clinical presentation 
MPS VI patients manifest a purely somatic disease with no primary cognitive impairment, 
characterized by a broad spectrum of clinical severity varying from slowly to rapidly progressing 
phenotypes, wherein the musculoskeletal, cardiopulmonary, gastrointestinal, and nervous 
systems, as well as the skin, cornea, and auditory tissue are frequently affected [14–16,21,26]. 
In the severe form of MPS VI, somatic symptoms may be present at birth, with newborns 
displaying enlarged head and deformed chest [14,26]. In the first 2–3 years of life, many features 
of dysostosis multiplex arise and physical growth stagnates around 6–8 years of age [14,16,21, 
26]. Multisystemic manifestations of severely affected patients include: facial dysmorphia; joint 
stiffness and contractures; hepatosplenomegaly; umbilical and inguinal hernias; absent or delayed 
puberty; visual and auditory deficits, which impair cognitive and learning capabilities; and central 
nervous system findings, as carpal tunnel syndrome, but with preserved intellect [14,16,21,26]. 
After one decade of life, they exhibit shortened trunk with protuberant abdomen, thoracolumbar 
gibbus, and reduced mobility [14,21,26]. Patients older than 10 years have cardiac problems, 
namely heart valve stenosis, often aggravated by progressive airway narrowing, upon which 
natural death in the second or third decades occurs, due to right ventricular failure [14,16,21,26]. 
Patients with mild MPS VI develop attenuated or slowly progressing somatic involvement 
later in life, typically affecting few systems simultaneously [16,26]. In general, diagnosis is made 
in teenage years or early adulthood, when skeletal alterations and a decrease in overall functional 
status become evident [16,26]. Mildly affected patients experience severe complications at some 
point in their lives, as joint degeneration, reduced respiratory function, spinal cord compression 
with myelopathy, and valvular heart lesions [14,16,26]. Natural death from cardiopulmonary 
failure may occur between 20 and 30 years of age, although some patients survive longer [21,26]. 
The clinical symptoms generally manifested in MPS VI are summarized in Table 1.3 and 
the characteristic features of affected patients are shown in Figure 1.4. 
 
Table 1.3. Clinical symptoms characteristic of MPS VI disease [14,16,21,26] 
Organ/system 
affected 
Clinical manifestations 
Musculoskeletal 
system 
– Macrocephaly – Thoracic deformity 
– Coarse facies – Degenerative joint disease 
– Claw-hand deformities – Vertebral body anomalies 
– Acetabulum hypoplasia – Dysplasia of the proximal femur 
– Shortened trunk – Thoracolumbar gibbus 
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Table 1.3. Clinical symptoms characteristic of MPS VI disease (cont.) [14,16,21,26] 
Organ/system 
affected 
Clinical manifestations 
Cardiovascular 
system 
– Aortic, mitral, and tricuspid valvular stenosis and/or insufficiency 
– Endocarditis fibroelastosis – Cardiomyopathy 
– Systemic hypertension  
Respiratory 
system 
– Chronic airway obstruction (secondary to short neck, hypoplastic 
mandible, elevated epiglottis, and tracheobronchomalacia) 
– Obstructive sleep apnea – Restrictive lung disease 
– Thick nasal discharge – Recurrent pneumonia 
Gastrointestinal 
system 
– Hepatomegaly – Splenomegaly 
– Umbilical and inguinal hernias  
Visual system 
– Corneal clouding – Glaucoma 
– Optic nerve alterations – Visual disability 
Auditory system – Otitis media – Hypoacusia 
Skin – Mild hirsutism  
Nervous system 
– Carpal tunnel syndrome – Communicating hydrocephalus 
– Meningeal thickening – Spinal cord compression 
 
 
 
   
Figure 1.4. Typical features of MPS VI patients [26]. Evidence of short stature, spine curvature [left], 
and coarse facial features (enlarged tongue, gingival hypertrophy, delayed dental eruption, depressed 
nasal bridge, and frontal bossing) [right]. 
 
Diagnosis 
The suspicion of MPS VI typically arises during clinical evaluation based on physical 
evidence: coarse facies, dysostosis multiplex, short stature, organomegaly, inguinal or umbilical 
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hernias, and corneal clouding are common findings [26,28]. Still, because this phenotype is similar 
to other MPSs, biochemical and genetic testing are required for an accurate diagnosis [26,28]. 
The elevation of total urinary GAGs can be used as a supportive test, in which levels above 
200µg GAGs/mg creatinine are found in severely affected patients, whereas levels below the 
threshold of 100µg GAGs/mg creatinine are seen in the milder form of MPS VI [26–28]. Since this 
method is only suggestive of a MPS disorder, the demonstration of DS accumulation in urine, with 
concomitant absence of all other GAGs, is necessary to reinforce suspicion of MPS VI [26,28]. 
Even so, the “gold standard” for MPS VI diagnosis is the evidence of severe deficiency of 
the ARSB activity in fibroblasts, leukocytes, serum, or dried blood spots, usually below 10% of the 
lower limit of normal enzyme activity, with the greatest disease severity being correlated with no 
detectable ARSB activity in vitro [16,26,28]. The identification of the normal activity of other 
lysosomal sulfatases is essential to rule out multiple sulfatase deficiency [26,28]. 
Gene sequencing for identifying pathological mutations in the ARSB gene can confirm the 
diagnosis of MPS VI, being also critical in carrier testing and prenatal diagnosis [26,28]. 
 
Treatment 
For many years, the clinical management of MPS VI was limited to supportive care and 
HSCT [26,28]. Because this disease affects multiple body systems, integrated care (e.g. physical 
and occupational therapy, nutrition counselling, symptom-based medications, and surgical 
interventions) has been important to optimize patients’ health and quality of life [18,21,26,28]. 
HSCT was, until recently, the only specific therapy available for MPS VI patients that 
provided long-term physiologic levels of ARSB delivered endogenously by donor cells [18,21,26, 
28]. Although it was shown to attenuate some somatic symptoms, it was only used in few cases 
due to lack of suitable donors, as well as significant mortality and morbidity risks [16,18,21,26, 
28]. After the availability of a specific ERT with proven efficacy and safety, HSCT has become an 
alternative therapeutic tool for this disease [16,18,21,28]. 
Since its approval in Europe, in 2006, ERT with genetically engineered human enzyme has 
been the first-line treatment for MPS VI [18,21,26,28]. This therapy with galsulfase (Naglazyme®, 
BioMarin Pharmaceutical Inc.) – a recombinant form of native human ARSB – is suitable for all 
symptomatic patients with confirmed diagnosis [18,21,26,28]. Regular treatment consisting of 
weekly intravenous administration of a dose of 1mg/kg, during a minimum infusion time of 4 
hours, proved to improve walking ability and pulmonary function, showing also positive effects 
on growth and puberty, as well as in the reduction of urinary GAG excretion [18,21,26,28]. 
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Even so, because ERT administered intravenously does not allow for galsulfase to reach 
the bone cells in order to correct the skeletal pathology, gene therapy is being investigated as a 
new approach to provide a stable source of exogenous enzyme to bone structures [17–19]. 
 
 
1.1.2. Immunological alterations in lysosomal storage diseases 
 
The lysosome, whose function is impaired in LSDs, represents a vital component of many 
immune cell processes, such as: autophagy; protein and lipid antigen processing and presentation 
by antigen presenting cells (APCs); phagocytosis; release of pro-inflammatory mediators by mast 
cells; and perforin secretion by CD8+ T cells [29–31]. The intralysosomal accumulation of 
substrates was already demonstrated in different immune cells in the context of LSDs, including 
circulating B cells [32], CD4+ and CD8+ T cells, natural killer (NK) cells [33], and monocytes [34]. 
Thus, lysosomal dysfunction in LSDs has potentially a negative impact in the normal functioning 
of the immune system, for example by causing direct damage to immune cells affected by 
lysosomal storage, or by impairing the correct activation and development of immune cells as well 
as their subsequent capacity of mounting an efficient protective response [29,30,35]. 
Up to the present day, most studies that characterized the immune system in LSDs were 
performed in murine models. A reduction of CD4+ T cells and an increase of CD8+ T cells were 
identified in the liver and spleen of Fabry disease mice [36]. A deficiency of thymic, hepatic, and 
splenic invariant natural killer T (iNKT) cells was also reported in the mouse models of Tay-Sachs 
disease [35], Fabry disease [35,36], multiple sulfatase deficiency [37], Sandhoff disease [35,37], 
Niemann-Pick disease type C1 [35,38], GM1 gangliosidosis [35,39], and Niemann-Pick disease 
type C2 [39]. With respect to APCs, an increase of splenic macrophages and a decrease of 
dendritic cells (DCs) were described in Sandhoff disease and GM1 gangliosidosis mice [35]. 
However, the levels of T cells, as well as CD4+ and CD8+ T cell compartments, were normal in the 
thymus, liver, and spleen of Niemann-Pick disease type C1 [38], GM1 gangliosidosis, and 
Niemann-Pick disease type C2 [39] mice. In the murine models of metachromatic leukodystrophy 
and Krabbe disease, there were no anomalies concerning iNKT cells [37]. 
In humans, studies evaluating the frequency of circulating leukocyte populations in LSD 
patients remain scarce. In Fabry disease, no alterations were detected in peripheral blood T cells 
[36], CD4+ T cells, NK cells [40], iNKT cells [36,40,41], and iNKT CD8+ cells [41]. In contrast, 
decreased numbers of CD8+ T cells, DCs, monocytes [40], and iNKT CD4+ cells [41] were seen in 
Fabry disease patients, along with higher levels of B cells [40] and iNKT CD4–CD8– cells [41]. In 
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Gaucher disease, it was found a reduction of circulating DCs [42] and CD4+ T cells, as well as an 
increase of CD8+ T cells, but no anomalies in iNKT cells [43]. In Niemann-Pick disease type C1 
patients, although the frequencies of iNKT cells [44], T cells, and B cells were normal, a deficiency 
of NK cells was observed [45]. 
 
In the particular case of MPSs, a limited number of studies have investigated, so far, the 
immune cell abnormalities present in this subclass of LSDs. In the mouse model of MPS VII, no 
alterations in CD4+ and CD8+ T cells were detected in the thymus, spleen, and lymph nodes, with 
the exception of a reduction in splenic CD4+ T cells [46]. The percentages of circulating DCs and 
CD4+, CD8+, and memory CD4+ T cell subsets were reduced in MPS I mice [30], but there were no 
changes in thymic, splenic, and hepatic iNKT cells [37]. In the MPS IIIB murine model, an increase 
of B cells, CD4+ and CD8+ T cells was identified in the spleen [47]. An analysis carried out in MPS 
II patients revealed normal levels of CD4+ and CD8+ T cells, but a decrease of circulating B cells 
and NK cells was reported [31]. 
 
In most studies regarding the immunological characterization of LSDs, iNKT cells were the 
lymphocyte population more frequently analyzed. Similarly, the iNKT cell frequency in MPS II and 
MPS VI diseases was also evaluated in our laboratory. The results showed no alterations in iNKT 
cells in MPS II patients [48] and MPS VI patients [49] as compared with control subjects, being 
consistent with previous works conducted in Fabry disease [36,40,41], Gaucher disease [43], and 
Niemann-Pick disease type C1 [44] patients. The B cell percentage was also assessed in our 
laboratory for MPS II and MPS VI diseases. Although no differences were observed in MPS II 
patients [48], a significant increase of B cells was found in MPS VI patients [49] comparing with 
control subjects, which was in accordance with a prior study in Fabry disease patients [40]. 
 
 
1.2. Invariant natural killer T cells 
 
iNKT cells are a highly conserved T cell subpopulation defined by the expression of NK 
lineage markers (e.g. CD161) and a CD1d-restricted, lipid-specific T cell receptor (TCR) [50–55]. 
Unlike other natural killer T (NKT) cells that exhibit an oligoclonal αβ TCR – type II NKT cells –, 
iNKT cells – type I NKT cells – express a semi-invariant TCR composed by an invariant α chain 
(Vα24Jα18 in humans and Vα14Jα18 in mice) combined with a limited, but not invariant, β chain 
repertoire (typically Vβ11 in humans, although in mice can be Vβ2, Vβ7, or Vβ8.2) [50–55]. 
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The tissue distribution and frequency of iNKT cells vary considerably among humans, 
although remaining stable within individuals, with higher levels typically found in women [50, 
53–55]. After developing in the thymus, some mature iNKT cells remain in this lymphoid organ 
whereas others migrate to the periphery, being mostly distributed between the adipose tissue, 
omentum, and liver, where they represent, respectively, 15–35%, 10%, and 1% of the lymphocyte 
population [50,53–55]. Lower similar iNKT cell levels are detected in the bone marrow, spleen, 
and peripheral blood, where they account for 0.01–1% of total lymphocytes [50,53,55]. 
 
Immune responses 
iNKT cells are responsive to lipid antigens presented by CD1d, a monomorphic major 
histocompatibility complex (MHC) class I-like molecule; this feature distinguishes them from 
conventional T cells, which typically identify peptide ligands bound to highly polymorphic MHC 
class I and II molecules [50–54]. iNKT cells recognize not only foreign lipids, essentially derived 
from microorganisms (e.g. glycolipids from Sphingomonas spp., Borrelia burgdorferi, Streptococcus 
pneumoniae), but also self-antigen lipids (e.g. membrane phospholipids) [50–54]. One of the most 
potent lipids known to be able to stimulate iNKT cells is α-galactosylceramide (α-GalCer), an 
exogenous marine sponge-derived glycolipid commonly used to study these cells [50,51,53]. 
Upon specific binding of the TCR to a high-affinity lipid antigen loaded in CD1d molecules 
at the surface of an APC (e.g. DCs, macrophages, B cells), activation and proliferation of iNKT cells 
are quickly induced [50–54]. The TCR signaling culminates fundamentally in rapid and abundant 
secretion of several T helper (Th) type 1 (e.g. interferon (IFN)-γ, interleukin (IL)-2) and type 2 
(e.g. IL-4, IL-10) cytokines [50–54]. This cytokine profile varies with CD4 and CD8 expression, 
according to which iNKT cells can be divided into three functional subsets: iNKT CD4+ cells 
release both Th1 and Th2 cytokines, while iNKT CD8+ cells and iNKT CD4–CD8– cells are mainly 
producers of Th1 cytokines [50,52–54]. Besides secreting copious amounts of Th1 and Th2 
cytokines – based on which are classified into iNKT1 and iNKT2 cells, respectively –, iNKT cells 
can produce Th17 cytokines (e.g. IL-17, IL-22) – iNKT17 cells – or share functional features with 
follicular helper T cells and secrete IL-5 or IL-6 cytokines – iNKTFH-like cells [51–53]. 
In addition to direct activation via TCR–CD1d/lipid interactions, iNKT cells may also be 
indirectly stimulated through cytokine production by APCs, readily recognized by constitutive 
cytokine receptors in resting iNKT cells [51–54]. Because many microbial pathogens do not 
express cognate lipid antigens, iNKT cell activity requires induction by pro-inflammatory 
cytokines (e.g. IL-12, IL-18), leading to responses that usually consist in the secretion of IFN-γ 
[51–54]. Besides providing an alternative pathway through which they can be activated in the 
absence of specific lipid antigens, this cytokine-driven stimulation of iNKT cells can also occur in 
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combination with TCR signals in the presence of low-affinity lipids, with both stimuli acting 
synergistically to promote a rapid and robust immune response [51–54]. 
The direct and indirect processes of iNKT cell activation are displayed in Figure 1.5. 
 
 
Figure 1.5. TCR- and cytokine-mediated activation of iNKT cells. Adapted from [53]. (A) iNKT cell 
activation by a strong foreign antigen is dominated by the TCR signal provided by a lipid–CD1d 
complex and has little dependence on APC-derived cytokines that are generated in response to the 
stimulation of pattern-recognition receptors (PRRs). (B) In cytokine-driven iNKT cell activation, PRR-  
-mediated stimulation of APCs leads to the secretion of pro-inflammatory cytokines (e.g. IL-12) that 
bind to specific receptors in iNKT cells; TCR signal is still required in most cases, being provided by 
low-affinity microbial lipids or self-lipid antigens. 
 
An additional iNKT cell action secondary to TCR-dependent signaling and inflammatory 
cytokines involves the acquisition of cytolytic activity, due to expression of cytotoxic granules (e.g. 
granzyme, perforin) like NK cells [50,52,54]. As a result, iNKT cells are able to kill different target 
cells, including APCs, regulatory T cells, as well as malignant and infected cells [50,53]. 
In this way, iNKT cells perform both innate-like and adaptive immune functions: the 
ability for rapidly mounting protective immune responses with minimal TCR involvement by 
releasing cytokines and producing cytolytic mediators, as well as the capacity to respond directly 
via specific TCR-mediated recognition of lipid antigens allow them to bridge the two arms of the 
immune system [50,52,54]. These actions can have either protective or harmful roles in several 
human pathologies, with the iNKT cells having already been implicated in cancer, allergic 
diseases, autoimmunity, and microbial infections [50,52–54]. 
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1.3. B lymphocytes 
 
As part of the humoral immunity of the adaptive immune system, B cells are widely 
recognized for their main role in the secretion of antibodies capable of recognizing an almost 
unlimited variety of antigenic epitopes (e.g. polysaccharides, proteins, lipids) of bacteria, viruses, 
and other disease-causing organisms [56–58]. Antibodies are immunoglobulin (Ig) molecules 
composed of four polypeptide chains – two heavy and two light chains –, both of which contain a 
variable region and a constant one [59,60]. The variability that enables each antibody to 
specifically bind a cognate antigen is conferred by the variable region, whereas the constant 
region allows Ig molecules to mediate effector functions [59,60]. Antibodies exist in two physical 
forms: (i) membrane-bound antibodies are a constitutive part of the B cell receptor (BCR), whose 
interaction with specific antigens elicits activation and proliferation of B cell clones, leading to 
abundant secretion of Ig molecules; (ii) soluble antibodies are released into the peripheral blood 
as effectors of the humoral immune system for neutralizing antigens or marking them for 
destruction [57,59,60]. According to the unique amino acid sequences present in the heavy chain’s 
constant region, five antibody isotypes can be distinguished: IgM, IgD, IgG, IgA, and IgE [60]. The 
general structure of an Ig molecule, as well as of the antigen-binding receptor of B cells, is 
represented in Figure 1.6. 
 
 
Figure 1.6. Basic structure of an antibody and of BCR. Adapted from [60]. (A) Two identical 
combinations of light and heavy chains are bound to each other to form a Y-shaped, four-chain Ig 
molecule. A variable region exists in each light and heavy chain, with the remainder of each chain 
forming a constant region. (B) The BCR is a multiprotein complex consisting of an antigen-binding 
surface Ig molecule associated with the signal-transducing Ig-α/Ig-β heterodimer, responsible for 
cellular activation upon specific ligand recognition. 
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Additional functions of B cells include antigen presentation via MHC molecules to activate 
T cell-dependent immune responses, regulation of DC and T cell actions through production of 
immunomodulatory cytokines, lymphoid tissue organization, and tumor immunity [57,58]. 
 
 
1.3.1. Development of B cell subpopulations 
 
In humans, several B cell compartments are encountered in the peripheral blood, together 
accounting for 5–15% of circulating lymphocytes, wherein the total B cell population generally 
changes with age: the global number of B cells in circulation usually rises during the first 2 years 
of life, followed by a decrease until early adulthood and stabilization in adult people, after which it 
starts to diminish again when individuals reach the sixth decade of life [57,61]. 
The various human peripheral blood B cell subsets are generated through a continuum of 
differentiation stages that take place in many tissues [56–58,61]. The development of B cells is 
initiated in primary lymphoid tissues (e.g. bone marrow and fetal liver), wherein committed 
precursors give rise to immature B cells of two different lineages – B-1 cells and B-2 cells –, which 
recirculate in the peripheral blood to complete their maturation in secondary lymphoid tissues 
(e.g. spleen, lymph nodes, mucosa-associated lymphoid tissues) and in bone marrow [56–58,61]. 
The developmental progression from pluripotent progenitors to functional B cells is defined by a 
changing in the expression pattern of several surface markers [58,62,63]. 
 
 
 Initial development of B cells in the fetal liver and bone marrow 
 
During embryonic life, hematopoietic stem cells (HSCs) in the fetal liver give rise to 
committed precursors that differentiate into the B-1 cell lineage [57,62,63]. After birth, bone 
marrow-derived HSCs generate committed progenitor cells that continually develop into the B-2 
cell lineage, which includes most B cell subpopulations, together known as B-2 cells [57,62,63]. 
The limitation of lifespan and differentiation-inducing factors (e.g. bone marrow stromal 
cells' surface receptors, lineage-specific cytokines, BCR ligands) drives B cell ancestors to compete 
among each other for growth resources, which subsequently stimulates them to go through a 
stepwise differentiation into functionally mature B cells [61,63]. Irrespective of whether they are 
generated in the bone marrow or fetal liver, early B cell progenitors (i.e. pro- and pre-B cells) are 
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Ig negative [56,58,61–63]. Once the rearrangement of Ig heavy and light chain gene segments is 
complete, these precursors evolve into immature B cells by expressing surface IgM antibodies, an 
event that triggers egress into the peripheral blood [56,58,61–64]. At this point, immature B cells 
have an intact BCR, required for B cell development and survival in the periphery [56,58,62–64]. 
 
 
 Further development of B cells in peripheral lymphoid tissues: differentiation into 
functionally and phenotypically distinct subpopulations 
 
After the negative selection process, the functionally immature IgM+ B cells whose BCRs 
do not exhibit self-reactivity leave the hematopoietic lymphoid tissues and migrate to secondary 
lymphoid organs for further maturation [56,61–64]. On the one hand, IgM-expressing immature B 
cells produced in the fetal liver enter the peripheral circulation to differentiate into B-1 cells [57, 
62]. On the other hand, IgM+ immature B cells originated in the bone marrow recirculate in the 
peripheral blood to finalize early B-2 cell development mainly in the spleen, as well as terminal 
differentiation of mature B-2 cells before migrating to other peripheral lymphoid organs, namely 
lymph nodes and mucosa-associated lymphoid tissues [56,57,61,62]. According to the maturation 
status, circulating B-2 cells are typically classified as transitional B cells, naïve follicular B cells, 
plasma B cells, and memory B cells [56,61]. Essentially all peripheral blood B-lineage cells are 
identified by CD19 expression, a component of the B cell co-receptor that provides stimulatory 
signals to BCR, contributing to the activation of mature B cells in the periphery [58,62,63]. 
 
 
1.3.1.1. B-1 cells 
 
B-1 cells represent a small IgM+ B cell subset that develops earlier in life than B-2 cells, 
being encountered primarily in the peripheral blood, peritoneum, and mucosae of human adults 
as a self-replenishing population, which comprises 1–9% of all circulating B cells [57,62,63,65]. 
 
Immune responses 
As part of the innate immune system, B-1 cells secrete spontaneously and constitutively 
the majority of natural, low-affinity IgM antibodies that recognize a variety of carbohydrate and 
lipid antigens present in most common microbial pathogens [57,58,62,63,65]. In this way, they 
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immediately provide an initial immune response against infection within the naïve host, 
especially in the peritoneal cavity, through T cell-independent mechanisms [57,62,63,65]. In 
addition, B-1 cells have immunosuppressive properties owing to secretion of IL-10 and can also 
act as APCs by presenting antigens and strongly stimulating T cells via CD80/86 [65]. 
 
Phenotypic characterization 
Despite the evidence for the existence of human circulating B-1 cells, their phenotype is 
not clearly defined as it is in mice, since they share surface antigens with memory B cells, 
monocytes/macrophages, and T cells; therefore, the profile of cell-surface marker expression in 
human B-1 cells has not yet been universally established and accepted [65–67]. 
 
 
1.3.1.2. Transitional B cells 
 
Immature IgM+ B-2 cells begin to mature rapidly in the peripheral blood and spleen via 
three transitional stages, wherein they successively give rise to T1, T2, and T3 B cells that express 
both IgM and IgD molecules, together accounting for 2–4% of all circulating B cells in adult people 
[56,61,62,64,68,69]. Transitional B cells then complete the first stage of B-2 cell differentiation in 
the spleen, where they mature into follicular or marginal zone B cells [56,61,62,64,68,69]. 
 
Immune responses 
Transitional B cells appear to respond to antigens that trigger T cell-independent immune 
responses (e.g. lipopolysaccharides) via rapid antibody production [58,69], but they also seem to 
exhibit a lower ability to proliferate and develop into antibody-secreting B cells in comparison 
with mature naïve follicular B cells [61]; therefore, their functions are not fully understood. 
 
Phenotypic characterization 
Transitional B cells exhibit features of an immature phenotype, as lack of responsiveness 
to BCR-mediated signaling due to overexpression of negative regulators (e.g. CD5) that counteract 
the reduced activation of BCR co-receptors (e.g. CD21) [61,68]. However, they also co-express 
surface IgM and IgD molecules like mature naïve follicular B cells, although transitional B cells 
present higher IgM and lower IgD expression as compared with naïve follicular B cells [58,61,68]. 
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1.3.1.3. Follicular B cells 
 
Most mature B-2 cells constitute the follicular B cell subset, defined by the production of 
both membrane-bound IgD and IgM antibodies with a single antigenic specificity [61–63]. Their 
co-expression is associated with the capacity to migrate between secondary lymphoid organs and 
the acquisition of functional competence, in which the naïve follicular B cells become responsive 
to antigen-specific BCR activation [61,62]. In human adults, they represent 60–70% of B cells in 
the peripheral blood, which they habitually recirculate while migrating between the spleen, 
lymph nodes, and mucosa-associated lymphoid tissues, where they reside in specialized niches – 
the B cell follicles [57,58,61,62,70]. 
 
Immune responses 
Mature naïve follicular B cells not yet exposed to an antigen circulate between the 
peripheral blood and secondary lymphoid tissues, searching for specific antigens while competing 
for entry into B cell follicles; unless these cells encounter their cognate antigen, they die within a 
few weeks by apoptosis [57,61–63]. 
Upon first exposure of naïve follicular B cells to a foreign antigen presented by APCs (e.g. 
follicular DCs, marginal zone B cells) and recognized by surface IgM or IgD molecules of the BCR 
complex, they are committed to one of three effector fates of humoral immunity, depending on the 
inherent BCR affinity and antigenic nature [58,61,63,64,70,71]. Those B cell clones bearing high-   
-affinity BCRs during T cell-dependent responses, or that bind to polysaccharide or lipid antigens 
and undergo activation without T cell help, are firstly selected for the generation of (i) short-lived 
plasma B cells outside lymphoid follicles, leading to immediate local antibody secretion early 
during an immune challenge [58,63,70,71]. In turn, low-affinity counterparts binding to protein 
antigens require direct contact with activated CD4+ T cells to complete the final stage of B-2 cell 
development in germinal centers (GCs) – central proliferative areas in lymphoid follicular loci –, 
being directed towards (ii) long-lived plasma B cell and (iii) memory B cell differentiation 
pathways to improve antibody affinity [56,58,61,63,64,70,71]. 
During the GC reaction in spleen, lymph node, and mucosa-associated lymphoid tissue 
follicles, antigen-activated B cells migrate repetitively between two distinct GC areas [56,58,61,63, 
71]. In the dark zone, they undergo vigorous proliferation, somatic hypermutation – increase in 
antigen binding capacity of antibodies due to point mutations in heavy and light chain genes –, 
and, eventually, Ig class switch recombination – change of Ig isotype from IgM/IgD to IgG, IgA, or 
IgE [56,58,61,63,64,70–72]. In the light zone, the improvement in Ig affinity is verified via re-          
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-contact of B cells with cognate antigens presented by follicular DCs [56,58,61,63,64,70,71]. After 
passing through many cycles of proliferation, affinity maturation, and antigen-driven selection, B 
cell clones with high-affinity surface antibodies are positively selected by CD4+ T cells to survive 
and proliferate, whereas low-affinity counterparts die by apoptosis [61,63,64,70–72]. The major 
outcome of GC reactions is the differentiation of higher affinity long-lived plasma B cells and 
memory B cells, which dominate the immune response, from low-affinity naïve B cells [61,63,70]. 
The antigen-dependent developmental stage of mature naïve follicular B cells occurring in 
the periphery that relies on T cell-mediated activation is represented in Figure 1.7. 
 
 
Figure 1.7. Differentiation of follicular B cells in secondary lymphoid tissues. Adapted from 
[63]. During antigen-dependent maturation, circulating naïve follicular B cells die within a few weeks 
unless they bind an antigen (Ag) specific to its surface Ig molecule. In T cell-mediated GC reactions, the 
antigen–BCR complex is internalized and the processed epitopes are presented to helper T cells (TH 
cells), which induce B cell proliferation, affinity maturation, and Ig class switching in peripheral 
lymphoid tissues. B cell clones bearing high-affinity surface Ig molecules are selected to develop into 
memory B cells and long-lived plasma B cells, culminating in high-affinity antibody (Ab) secretion. 
 
Phenotypic characterization 
The combination of IgM (or IgD) and CD27 surface markers – the last one being typically 
associated with the occurrence of somatic hypermutation in GCs – is a strategy frequently used to 
discriminate B cells with a more naïve phenotype (IgM+) from those that are more differentiated 
(CD27+) [64,69,73]. In this way, mature naïve follicular B cells are identified as CD19+IgM+CD27– 
cells (this phenotypic profile is also applicable to circulating transitional B cells) [64,69,73]. 
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1.3.1.4. Plasmablasts and plasma B cells 
 
Most of the progeny of naïve follicular B cells that proliferated in response to antigen 
stimulation and T cell help gives rise initially to plasmablasts, pre-effector B cells showing on-        
-going cell division and antibody production [57,61,64,71]. Plasmablasts look for survival niches 
in the bone marrow or mucosa-associated lymphoid tissues to differentiate into plasma B cells, 
defined by enlarged size, lacking of proliferative activity, and presence of few or none surface Ig 
molecules [56,57,61,63,64,71]. In humans, both subsets are found at very low frequencies in the 
peripheral blood of healthy individuals, corresponding to 1–3% of adult circulating B cells [61,64]. 
However, under circumstances of immune activation (e.g. acute infections), high levels of newly-   
-generated plasmablasts and mature plasma B cells are detected in circulation [61,64]. 
 
Immune responses 
Plasma B cells constitute terminally differentiated B cells that are committed to abundant 
antibody secretion to assist the destruction of pathogens [57,61,64,71]. While differentiation of 
naïve follicular to plasma B cells conduces mostly to the secretion of IgM in primary immune 
responses, activation of memory B cells during subsequent exposures to the same antigen leads to 
the production of enormous amounts of high-affinity, somatically mutated IgG or IgA [57,61,71]. 
For humoral immunity to be sustained throughout a person’s life, continuous generation 
of antibodies is mandatory due to its very short half-life, which can fluctuate from only a few days 
(e.g. IgM, IgA) to some weeks (e.g. IgG) [61]. On this basis, two types of antibody-secreting cells 
are distinguished [56,70,71]. Short-lived plasma B cells are originated during T cell-independent 
reactions in extrafollicular foci and early in T cell-mediated responses in B cell follicles, being 
found in secondary lymphoid organs and non-lymphoid tissues [70,71]. By producing low-affinity 
antibodies that form immune complexes with antigens in B cell follicles, they provide an initial, 
temporary rapid defense while GCs are being prepared to yield a more sustained protection [58, 
70,71]. In turn, long-lived plasma B cells are generated during T cell-dependent GC reactions and 
acquire the ability to home to the bone marrow, where they are maintained for extended periods 
by cytokines of the BAFF family [56,58,61,64,70,71]. Through the persistent secretion of low 
levels of high-affinity antibodies for months or even years after an infection be eradicated, they 
confer immediate protection if the same invading organism is encountered later [58,61,64,70,71]. 
 
Phenotypic characterization 
The peripheral blood fraction of newly-generated plasmablasts and mature plasma B cells  
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migrating from the bone marrow exhibits low levels of membrane-bound Ig molecules and 
heterogeneous CD138 expression [61,64]. Since the adhesion molecule CD138 is acquired during 
plasmacytic differentiation and, hence, is restricted to circulating plasmablasts and plasma B cells 
as compared with other peripheral blood B cells, the subset of plasmablasts and plasma B cells in 
the peripheral circulation is typically defined as CD19+dCD138+/– cells [61,64,65]. 
 
 
1.3.1.5. Memory B cells 
 
A minority of antigen-activated follicular B cells emerges from GCs during T cell-mediated 
reactions and acquires the ability to survive in the periphery for long periods without continuous 
antigenic stimulation [56,57,71]. These memory B cells are antigen-experienced cells capable of 
mounting rapid adaptive responses for neutralizing and eliminating antigens already encountered 
in the past, and express high levels of the anti-apoptotic protein Bcl-2 that contribute to their long 
lifespan [58,64,70,71]. In human adults, some memory B cells reside in the lymphoid organ where 
they were generated, whereas others circulate between the peripheral blood and antigen-draining 
lymphoid tissues, representing 30–40% of all circulating B cells [61,71]. 
 
Immune responses 
In a secondary immune reaction, memory B cells recognizing specific antigens rapidly go 
through several additional cycles of proliferation in GCs, after which many of them provide the 
host with a burst of short-lived plasma B cells or differentiate into high-affinity long-lived plasma 
B cells, while a small fraction still persists as memory B cells [57,58,61,70–72]. Due to such ability 
to promptly generate intensified immunizing responses against invading pathogens that formerly 
infected the host – immune memory –, they can eradicate a second infection more quickly than 
naïve follicular B cells in a primary challenge (3–5 versus 7–10 days, respectively) [63,70–73]. 
The repeated activation of memory B cells via antigen binding and T cell help conduces to 
extensive Ig isotype switching in GCs and increased expression of surface Ig molecules other than 
IgM and IgD [57,61,63,71]. About half of peripheral blood memory B cells exhibit mutated antigen 
receptors with high-affinity IgG or IgA antibodies – switched memory B cells [57,61,64,71]. Most 
of the remaining memory B cells still exhibit both membrane-bound IgM and IgD – non-switched 
memory B cells – or IgM molecules solely – IgM-only memory B cells –, being collectively known 
as IgM memory B cells, whose development seems to be independent of GC formation [61,72,73]. 
Beyond that, some IgG+ and IgA+ memory B cells are not classical switched memory B cells due to 
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lack of CD27 expression – double-negative memory B cells –, which account for 5% of circulating 
B cells and appear to be transient effectors that did not yet conclude the GC reaction and acquire 
CD27, being at an earlier stage of development regarding affinity maturation [61,64,73]. 
 
Phenotypic characterization 
Memory B cells are recognized for expressing CD27, an activation marker correlated with 
great proliferative capacity, aptitude for antigen presentation, and differentiation into antibody-   
-secreting cells [64,69,73]. Since plasmablasts and plasma B cells are rare in the peripheral blood 
of healthy individuals, most circulating CD27+ B cells are identified as memory B cells [64,73]. To 
distinguish the various memory B cell subsets, the expression of IgM (or IgD) and CD27 surface 
markers is evaluated: switched memory B cells are CD19+IgM–CD27+, IgM memory B cells are 
CD19+IgM+CD27+, and double-negative memory B cells are CD19+IgM–CD27– [64,69,73]. 
 
 
1.3.1.6. Marginal zone B cells 
 
Mature marginal zone B cells constitute a B-2 cell subpopulation with limited diversity 
that expresses high levels of membrane-bound IgM molecules [62]. In humans, they do not 
generally circulate in the peripheral blood; instead, they can be found primarily residing near the 
marginal sinus of the spleen and in the outer extrafollicular rim in lymph nodes [57,62,72,74]. 
 
Immune responses 
Marginal zone B cells are innate-like cells that, similarly to B-1 cells, secrete natural IgM 
antibodies against polysaccharide and lipid ligands in the absence of antigenic stimulation [57,58, 
62,74]. Upon direct contact with antigens and supported by splenic B cell helper neutrophils, they 
are capable of rapidly developing into extrafollicular short-lived plasma B cells that release IgM 
antibodies, being the first line of defense against blood-borne pathogens [56,62,74]. Besides their 
actions in T cell-independent humoral immunity, marginal zone B cells mediate antigen capture, 
transport into spleen and lymph node follicles, and presentation to follicular B cells [57,62,74]. 
 
Phenotypic characterization 
Marginal zone B cells are best defined in rodents and, although they seem to share the 
phenotype of IgM memory B cells, there is still uncertainty on their identity in humans [58,62,74]. 
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1.3.1.7. Regulatory B cells 
 
A novel, yet less well understood, human B-2 cell subset includes regulatory B cells, which 
are thought to be representative of 1–3% of splenic B cells [57]. These cells appear to suppress 
excessive tissue-specific inflammation and immune reactions that can lead to autoimmunity, via 
secretion of the anti-inflammatory cytokine IL-10 and the growth factor TGF-β [57,58,64]. The 
surface marker expression in human regulatory B cells remains a matter of debate [57,64]. 
 
The overall developmental process of the B-2 cell lineage is schematized in Figure 1.8. 
 
 
Figure 1.8. Developmental stages of the B-2 cell lineage. Adapted from [56]. Early B-2 cell 
development produces immature IgM-expressing B cells from bone marrow-derived HSCs that, after 
few transitional stages in the peripheral blood, mature into IgM+IgD+ follicular and marginal zone B 
cells. The latest generate IgM-secreting short-lived plasma B cells outside B cell follicles. Follicular B 
cells complete differentiation into short-lived plasma B cells without T cell help, or into long-lived 
plasma B cells and memory B cells, which express high-affinity IgG or IgA antibodies, under T cell-         
-dependent activation in GCs. 
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1.3.2. Transformation of peripheral B cells by Epstein–Barr virus 
 
Epstein–Barr virus (EBV) is a human lymphocryptovirus that belongs to the subfamily 
Gammaherpesvirinae of herpesviruses [75]. As a member of the family Herpesviridae, EBV is a 
double-stranded DNA virus composed mainly of: a core, containing the viral genome; a protein 
capsid, where the linear DNA molecule is densely packaged; a tegument, which consists of a 
proteinaceous layer surrounding the nucleocapsid; and an envelope, an external lipid bilayer 
carrying viral glycoproteins [75,76]. 
By adulthood, most humans have been infected by EBV, which is associated with several 
pathologies as Burkitt’s lymphoma and infectious mononucleosis [75,77,78]. EBV is particularly 
known for having tropism for resting primary B cells, wherein naïve follicular and memory B cell 
subsets are the main cellular targets both in vivo and in vitro, though this orally transmitted 
herpesvirus can also infect epithelial cells [76,77,79–81]. The generation of EBV-transformed B 
cell lines in vitro is possible owing to the capacity of the virus to establish a latent infection that 
continuously induces the stable expansion of B cells, via expression of few viral genes that prevent 
apoptosis, regulate cellular activation and proliferation, and maintain viral latency [76–81]. 
 
The entry of EBV virions into B cells relies on the high-affinity interaction between the 
major viral envelope glycoprotein gp350/220 and the complement receptor type 2 (CR2, or 
CD21), which acts as an EBV receptor on the surface of target cells [76,78,79]. A second viral 
envelope glycoprotein gp42 attaches to human leukocyte antigen (HLA) class II molecules that 
serve as a cellular co-receptor [76,78,79]. Both interactions are essential for the effective entry of 
EBV into B cells, although they are not required for the much less efficient infection of epithelial 
cells [76,79]. 
After such interactions have been established, adsorption and endocytosis of EBV virions 
are quickly triggered, followed by fusion of the viral envelope with a cellular endocytic vesicle [76, 
78]. As a consequence of EBV uncoating, the genomic material encapsidated in the protein shell is 
released into the cytoplasm, after which viral DNA is delivered into the nucleus [76,78]. 
During subclinical primary infections in vivo and B cell transformation in vitro, the double-
-stranded DNA molecule of EBV does not enter the cell nucleus in order to be massively replicated 
and produce progeny virions; instead, the viral genome is maintained as a covalently closed, 
circular extrachromosomal episome with only 5–100 copies per infected cell, which replicates 
synchronically with cellular DNA [77,78,80,82,83]. In this non-producing latent infection, a 
limited number of viral genes are expressed under careful regulation to generate nine virally 
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encoded proteins that drive the target B cell into cell cycle while maintaining viral latency, thus 
inducing the survival and continuous outgrowth of EBV-infected B cells [77–80,82,83]. Their 
phenotype is typically characterized by the expression of six Epstein–Barr nuclear antigens 
(EBNAs-1, -2, -3A, -3B, -LP, and -3C; alternatively, EBNAs-1–6) and three latent membrane 
proteins (LMPs-1, -2A, and -2B) [77–81,83]. Of these, EBNAs-1, -2, -3A, -LP, and -3C, as well as 
LMP-1, are required for the immortalizing effect of EBV, with EBNA-2 and LMP-1 as the most 
relevant viral proteins [77,78,80,81,83]. 
The phenotypic change resulting from expression of virally encoded proteins renders the 
infected B cells immunogenic and, therefore, stimulates T cell surveillance, wherein CD8+ T cells 
are dedicated to readily detect and eradicate transformed B cells [77,79,80]. However, before this 
EBV-mediated cell expansion is contained by the immune system, some infected B cells manage to 
switch off viral gene expression and counteract antigen presentation by down-regulating surface 
HLA expression, in order to escape from T cell recognition; as so, these cells are able to reach the 
memory B cell pool and achieve long-term persistency as resting cells that carry silent viral 
genomes and are not immunogenic [77,79,80,83]. 
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2. AIMS 
 
Considering a previous work conducted in our laboratory that identified a significant 
increase in the frequency of B cells in MPS VI patients [49], the main purpose of this thesis was to 
study the B cells in MPS II and MPS VI diseases. The more specific aims were: 
 To analyze the frequency of the major peripheral blood leukocyte populations in MPS 
II and MPS VI patients; 
 To characterize the frequency of the B cell and T cell subsets in MPS II and MPS VI 
patients; 
 To produce EBV-transformed B cell lines from MPS II and MPS VI patients; 
 To evaluate the efficacy in the production of EBV-transformed B cell lines from MPS II 
and MPS VI patients; 
 To assess the phenotype of EBV-transformed B cell lines from MPS II and MPS VI 
patients. 
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3. MATERIALS AND METHODS 
 
During the period of my thesis, the experimental activities comprising (i) the analysis of 
the B cell and T cell populations by flow cytometry and (ii) the production of EBV-transformed B 
cell lines in vitro were performed using peripheral blood samples from MPS II and MPS VI patients 
as well as control subjects. Upon their isolation, peripheral blood mononuclear cells (PBMCs) 
were incubated with EBV infectious virions (previously obtained from B95-8 cell cultures) to 
induce B cell transformation. The remaining PBMCs were used for flow cytometry in order to 
determine the frequency of circulating B cell and T cell subsets. After the culture of infected B cells 
over a period of 35 days, the phenotypic characterization through flow cytometry and the freezing 
of EBV-transformed B cell lines were executed. The experimental design of the study conducted 
during the time I worked in the laboratory is shown in Figure 3.1. 
 
 
Figure 3.1. Experimental design of the study. 
 
Prior to the start of this thesis, a first analysis of the frequency of several leukocyte 
populations – T cells, NK cells, B cells, and monocytes – was carried out by Luz Maia, Nuno Lopes, 
and Cátia Pereira for six of the ten MPS II patients and for all the sixteen MPS VI patients included 
in the study of the immune system alterations in MPS II and MPS VI diseases. During my work in 
the laboratory, I performed a second determination of the percentage of B cells and T cells for two 
of the ten MPS II patients and for ten of the sixteen MPS VI patients, as well as the analysis of four 
MPS II patients for the first time. 
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3.1. Subject selection and blood sample collection 
 
In the study that focused on the characterization of the immune system in MPS II and MPS 
VI diseases and which was mostly performed before I have worked in the laboratory, a total of ten 
MPS II patients, sixteen MPS VI patients, and twenty-seven control subjects were evaluated. More 
specifically, during the period of my thesis, a total of six MPS II patients and ten MPS VI patients, 
as well as nine control subjects were analyzed for the frequency of circulating B cell and T cell 
populations. Of these, five MPS II patients, five MPS VI patients, and all control subjects were 
included in the study concerning the production and phenotyping of EBV-transformed B cell lines. 
The group of MPS II patients was composed entirely by males as this is an X-linked 
disease, while the MPS VI patient group comprised eight females and eight males. These patients 
were recruited by their physicians, after their and/or their parents' informed consent, and the 
blood samples collected at Centro Hospitalar de São João (Porto, Portugal), Hospital Geral de Santo 
António (Porto, Portugal), Hospital de Santa Maria (Lisbon, Portugal), Hospital Pediátrico de 
Coimbra (Coimbra, Portugal), Hospital Clínicas de Porto Alegre (Porto Alegre, Brazil), and Hospital 
São João de Deus (Barcelona, Spain), under an agreement between Instituto de Biologia Molecular e 
Celular (IBMC; Porto, Portugal) and these institutions, relying on the approval of their ethical 
committees. With the exception of two MPS II patients, all individuals in both groups were under 
ERT at the time of the first analysis. The treatment consisted in the intravenous infusion of a 
recombinant form of the enzyme iduronate-2-sulfatase (idursulfase, Elaprase®) for MPS II 
patients or arylsulfatase B (galsulfase, Naglazyme®) for MPS VI patients. The main characteristics 
of the MPS patients (age at the first analysis, sex, genetic mutation(s), and ERT information) that 
participated in the studies on the immune system in MPS II and MPS VI diseases as well as on the 
generation of EBV-transformed B cell lines are described in Table 3.1. 
The control group analyzed with the aim of characterizing the immunological alterations 
in MPS II and MPS VI patients consisted of nine females and eighteen males, including sixteen 
children and eleven adults. Upon receiving the informed consent from these subjects, which were 
blood donors at Centro Hospitalar de São João and Hospital de Valongo (Valongo, Portugal), the 
blood samples were obtained under a protocol between IBMC and these institutions, with the 
approval of their ethics commission. In the control group of the work performed for producing 
EBV-transformed B cell lines, six females and three males were recruited by Fátima Macedo at 
IBMC, after the approval of the internal ethics board and obtainment of the informed consent 
from these adult voluntary donors. The blood samples were collected at Centro de Genética 
Preditiva e Preventiva (Porto, Portugal) by the nurse that collaborated in this project. 
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Table 3.1. Characterization of the MPS II and MPS VI patients included in the analysis of 
the immune system in MPS II and MPS VI diseases, as well as in the production of EBV-    
-transformed B cell lines 
Patient Age Sex Mutation(s) ERT Study 
M
P
S
 I
I 
#1 28 M C2846G>C; tR95T, exon 3 Yes 1 
#2 9 M NA Yes 1 
#3 23 M NA Yes 1 
#4 9 M p.G340R; c.1018G>C Yes 1, 2 
#5 7 M c.241C>T; p.Q81X Yes 1, 2 
#6 15 M c.1130G>C; p.G336R Yes 1 
#7 16 M NA Yes 1, 2 
#8 12 M NA No 1, 2 
#9 17 M NA No 1, 2 
#10 18 M NA Yes 1 
M
P
S
 V
I 
#1 18 F c.944G>A; p.R315Q Yes 1 
#2 20 M R315Q Yes 1 
#3 23 F c.215T>G; p.L72R Yes 1 
#4 18 M p.D54N Yes 1 
#5 4 F NA Yes 1 
#6 14 F NA Yes 1, 2 
#7 27 F NA Yes 1 
#8 23 M NA Yes 1 
#9 13 M NA Yes 1 
#10 11 F IVS5+2; c.238delG Yes 1 
#11 11 F IVS5+2; c.238delG Yes 1 
#12 13 F NA Yes 1 
#13 19 M R315Q+S384N; L72R Yes 1, 2 
#14 13 M 
Heterozygous IVS5-8T>G; c.1143-8T>G; 
c.149T>A (p. L50X) 
Yes 1, 2 
#15 7 M 
Heterozygous c.1533_1555Del; 
c.1336G>A (p.G446S) 
Yes 1, 2 
#16 13 M Homozygous IVS5-8T>G; c.1143-8T>G Yes 1, 2 
M: male; F: female; NA: not available; ERT: enzyme replacement therapy; Study 1: study on the 
characterization of the immune system in MPS II and MPS VI diseases; Study 2: study on the 
generation and phenotypic characterization of EBV-transformed B cell lines. 
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The samples of peripheral blood from MPS II and MPS VI patients were collected into 
ethylenediamine tetraacetic acid (EDTA)-containing tubes. For MPS patients that were under ERT, 
blood collection was executed before intravenous administration of the recombinant enzyme. 
 
 
3.2. Isolation of peripheral blood mononuclear cells 
 
Within 24 hours upon receipt of the blood samples, PBMCs were isolated through a 
process of density gradient centrifugation using the Histopaque®-1077 medium (Sigma), under 
sterile conditions. The blood was laid over an equal amount of Histopaque®-1077 and centrifuged 
at 400g for 30 minutes, without break. After centrifugation, the various blood constituents could 
be distinctly visualized as separate layers: PBMCs were positioned between the plasma and the 
Histopaque®-1077 medium as a narrow cell ring, as represented in Figure 3.2. Most plasma was 
collected, centrifuged at 2,500rpm, 4°C, for 30 minutes, and stored at –20°C. Following PBMC 
collection, cells were washed with 10mL of phosphate buffered saline 1x (PBS 1x; see appendix) 
and centrifuged at 250g for 10 minutes. Then, PBMCs were incubated for 10 minutes with 10mL 
of ammonium-chloride-potassium (ACK) lysing buffer (see appendix), after which 10mL of PBS 1x 
were added and cells centrifuged at 250g for 10 minutes. Upon resuspension of PBMCs in 10mL of 
PBS 1x, viable cells were counted under the microscope through the method of trypan blue and 
utilizing a Neubauer chamber. Following cell count, PBMCs were used for the generation of EBV-   
-transformed B cell lines and for flow cytometry analysis. 
 
  
Figure 3.2. PBMC isolation by density gradient centrifugation with Histopaque®-1077 medium. 
 
← Plasma, platelets 
Blood → 
Histopaque
®
-1077 → 
← Erythrocytes, 
    granulocytes 
← Histopaque®-1077 
400g 
30 minutes 
← PBMCs 
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3.3. Production of EBV infectious virions 
 
For the production of high titers of EBV infectious virions, the marmoset B95-8 cell line 
available in our laboratory was used. Under sterile conditions, cells were cultured in 10mL of 
RPMI 10% inactivated fetal bovine serum (iFBS) (see appendix), and incubated at 37°C, 5% CO2. 
On the following day, the B95-8 cell culture was splitted 1:3 in RPMI 10% iFBS and incubated at 
37°C, 5% CO2, until the medium had a strong yellow coloration. A week later, cells were 
centrifuged at 1,200rpm for 10 minutes, after which the supernatant with EBV infectious virions 
was collected and passed through a 0.45µm filter. Aliquots of 1mL and 4,5mL of the filtered EBV-  
-containing supernatant were stored at –80°C until their use for the generation of EBV-                       
-transformed B cell lines. Given that the lifetime of EBV is reduced when maintained at 37°C, the 
aliquots of infectious virions were only thawed for use once; they were not frozen again for 
reutilization due to the risk of EBV's infectivity being affected by successive thawing processes. 
 
 
3.4. Transformation of B cells by EBV 
 
For the viral infection and transformation of peripheral blood B cells, EBV infectious 
virions from the B95-8 culture supernatant were used, along with the previously isolated PBMCs. 
After quick thawing on a 37°C water bath, 1mL per well of EBV-containing supernatant was plated 
in a 24-well plate, under sterile conditions. Upon resuspension of PBMCs at 2x106 cells/mL in 
RPMI 20% iFBS (see appendix), 1mL per well of PBMCs was transferred to the previous wells. 
Finally, cyclosporine A (Calbiochem) at 1µg/mL was added to each well to suppress T cell and NK 
cell function, after which the cultures were incubated at 37°C, 5% CO2. Of note, the aliquots of 
EBV-containing supernatant used in the production of all EBV-transformed B cell lines came from 
the same stock of EBV infectious virions. 
 
 
3.5. Culture of EBV-transformed B cells 
 
On day 7 post-infection, approximately half the transformation medium in each well was 
discarded and replaced by an equal volume of RPMI 20% iFBS (see appendix), followed by cell 
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incubation at 37°C, 5% CO2. On days 14 and 21 post-infection, after removing about half the 
culture medium in each well, the rupture of EBV-transformed cell clusters was promoted through 
vigorous resuspension of the cultures in order to stimulate cell proliferation. The final volume of 
each well was again adjusted to 2mL by adding RPMI 20% iFBS and cells were incubated at 37°C, 
5% CO2. From that moment, this procedure was performed twice a week until day 35 post-              
-infection and, occasionally, the cultures were splitted in RPMI 20% iFBS. 
The growth of virally infected cell cultures was evaluated by weekly observation under 
the microscope, along with its documentation through photographs. The wells still showing 
actively proliferating cell aggregates after 35 days of culture were considered to contain EBV-        
-transformed B cell lines. 
 
 
3.6. Flow cytometry 
 
For studying the frequency of the major peripheral blood leukocyte populations – T cells, 
NK cells, B cells, and monocytes –, up to 1x106 PBMCs per well were stained extracellularly in a 
round-bottomed 96-well plate. Upon cell addition to the wells, PBMCs were collected through a 
short spin at 1,200rpm for 2 minutes. After discarding the supernatant and vortexing the plate, 
PBMCs were resuspended in 25µL of fluorochrome-conjugated antibody/tetramer mixes diluted 
in PBS 0.2% BSA 0.1% NaN3 (flow cytometry solution; see appendix) and incubated during 20 
minutes, at 4°C, in the dark. The antibodies and tetramer listed in Table 3.2 were used in PBMCs 
flow cytometry. 
Once the incubation period ended, stained PBMCs were washed three times by adding 
100–200µL of flow cytometry solution, followed by centrifugation at 1,200rpm for 2 minutes, 
rejection of the supernatant, and resuspension of cells in the vortex. Then, PBMCs were 
resuspended in 400µL of PBS 1% formaldehyde (cell fixing solution; see appendix) and 
transferred to FACS tubes provided with a filter. The filtered PBMCs were acquired on the same 
day, or kept at 4°C in the dark to be acquired on the next day. 
 
Furthermore, for the phenotypic characterization of EBV-transformed B cell lines, the 
extracellular staining of transformed B cells was executed on day 35 post-infection by following 
the experimental protocol described above and using the fluorochrome-labelled antibody mix 
listed in Table 3.3. 
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Table 3.2. Antibodies and tetramer used in flow cytometry to identify and characterize 
phenotypically the T cell, iNKT cell, NK cell, and B cell populations 
Antibody Clone Fluorochrome Brand 
Anti-human CD3 SK7 PerCP-Cy5.5 eBioscience 
Anti-human CD4 RPA-T4 PE-Cy7 eBioscience 
Anti-human CD8 RPA-T8 APC-eFluor 780 eBioscience 
Anti-human CD19 HIB19 FITC eBioscience 
Anti-human CD27 O323 PE eBioscience 
Anti-human CD45RA MEM-56 APC ImmunoTools 
Anti-human CD56 MEM-188 FITC eBioscience 
Anti-human CD138 MI15 APC BioLegend 
Anti-human CD161 HP-3G10 eFluor 450 ImmunoTools 
Anti-human CCR7 150503 FITC R&D Systems 
Anti-human IgM MHM-88 APC BioLegend 
PBS57-loaded hCD1d 
tetramer 
– PE 
National Institute of 
Health tetramer core 
facility 
APC: allophycocyanin; APC-eFluor 780: allophycocyanin conjugated with eFluor 780; FITC: 
fluorescein isothiocyanate; PE: phycoerythrin; PE-Cy7: phycoerythrin conjugated with cyanin-7; 
PerCP-Cy5.5: peridinin-chlorophyll protein complex conjugated with cyanin-5.5. 
 
 
Table 3.3. Antibodies used in flow cytometry to characterize phenotypically the EBV-        
-transformed B cell lines 
Antibody Clone Fluorochrome Brand 
Anti-human CD19 HIB19 PE-Cy7 eBioscience 
Anti-human CD27 O323 PE eBioscience 
Anti-human IgM MHM-88 APC BioLegend 
APC: allophycocyanin; PE: phycoerythrin; PE-Cy7: phycoerythrin conjugated with cyanin-7. 
 
 
PBMCs and EBV-transformed B cells were acquired in a 3-laser BD FACSCanto™ II (BD 
Biosciences) flow cytometer, using the BD FACSDiva™ software (BD Biosciences). Before data 
acquisition, both unstained and single stained controls were analyzed to adjust the voltage of 
sample acquisition and compensate samples. In PBMCs flow cytometry, data acquisition was 
performed as follows: up to 20,000 events for B cells, up to 2,000 events for iNKT cells, and up to 
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10,000 events for monocytes were acquired. In the case of EBV-transformed B cell lines, up to 
40,000 events were acquired inside the gate of B cells. All flow cytometry analyses were 
performed using the FlowJo software (Tree Star). 
 
 
3.7. Cryopreservation of EBV-transformed B cell lines 
 
EBV-transformed B cell lines were centrifuged at 1,600rpm for 5 minutes, after which up 
to 5–20x106 cells were gently resuspended in 1mL of iFBS 10% DMSO (freezing medium; see 
appendix) and quickly transferred to cryovials placed on ice by slowly pipetting 1mL per vial. 
Cells were gradually cooled by placement of the cryovials into a freezing container (Mr. Frosty®), 
which was stored overnight at –80°C. In the following day, the vials were moved to the liquid 
nitrogen tank for prolonged storage at –160°C. 
 
 
3.8. Thawing of EBV-transformed B cell lines 
 
Two cryovials containing EBV-transformed B cells (14x106 cells) were removed from the 
liquid nitrogen tank and immediately placed on a 37°C water bath. When cell suspension was 
completely thawed, cells were resuspended in 10mL of cold PBS 1x (see appendix) and 
centrifuged at 1,600rpm for 5 minutes. Upon resuspension in 5mL of RPMI 20% iFBS (see 
appendix), cells were transferred to a T25 culture flask and incubated at 37°C, 5% CO2. Cells were 
cultured over a week and growth documented through photographs, after which they were stored 
again in liquid nitrogen following the protocol described above. 
 
 
3.9. Statistical analysis 
 
All statistical analyses were performed using the GraphPad Prism 6 software. The normal 
distribution of each variable was determined using the Shapiro–Wilk test. For the comparison of 
each variable between several groups, the parametric one-way ANOVA test was applied when 
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variables were normally distributed, whereas the non-parametric Kruskal-Wallis test was used 
when variables did not follow a normal distribution. For the comparison of two analysis of a 
certain variable within each group, the parametric Student's t-test was employed when variables 
followed a normal distribution, while the non-parametric Mann–Whitney U test was utilized when 
variables were not normally distributed. The correlations were assessed through the parametric 
Pearson correlation coefficient when variables presented a normal distribution or through the 
non-parametric Spearman correlation coefficient when variables did not follow a normal 
distribution. Values of p<0.05 were considered statistically significant. 
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CHAPTER I 
CHARACTERIZATION OF THE IMMUNE SYSTEM IN MPS II 
AND MPS VI PATIENTS – MANUSCRIPT IN PREPARATION
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4. CHAPTER I – RESULTS 
 
Most of the results concerning the characterization of the immune system in MPS II and 
MPS VI diseases were already available in our laboratory when I started to develop this thesis. 
During the time I worked in the laboratory, I completed the study of the frequency of B cell and T 
cell populations in some MPS II and MPS VI patients, either for the first time in the case of four of 
the ten MPS II patients, or as a second determination for two out of ten MPS II patients and for ten 
out of sixteen MPS VI patients. In addition, I contributed to the statistical analysis of the results 
presented hereinafter in this chapter, as well as to the writing of the respective research paper. 
 
 
4.1. MPS patients and control subject characteristics 
 
In the study on the frequency of peripheral blood leukocyte populations in MPS II and 
MPS VI diseases, ten male MPS II patients with a mean age of 15.4 ± 6.6 years (range: 7–28 years), 
as well as sixteen MPS VI patients, including eight females and eight males, with a mean age of 
15.4 ± 6.1 years (range: 4–27 years) were analyzed. 
In turn, the control group consisted of twenty-seven apparently healthy individuals with a 
mean age of 16.8 ± 7 years (range: 6–30 years), of which nine were females and eighteen were 
males. There is no statistically significant difference with respect to age between these control 
subjects and both groups of MPS patients since they were age-matched. 
 
 
4.2. T cell and T cell subset frequency in MPS II and MPS VI patients 
 
T cells are involved in the recognition of peptide and lipid antigens, constituting the 
mediators of cellular immune responses of the adaptive immunity. In this study, the percentage of 
T cells (CD3+ cells) and their two major subsets – helper T cells (CD3+CD4+ cells) and cytotoxic T 
cells (CD3+CD8+ cells) – was evaluated in all MPS II and MPS VI patients as well as control 
subjects. The gating strategy used to identify T cells and their subpopulations by flow cytometry is 
shown in Figure 4.1. 
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Figure 4.1. Flow cytometry analysis of T cells and T cell subsets. After creating a lymphocyte gate 
in a forward scatter and side scatter cytogram (A), T cells are identified as CD3-expressing 
lymphocytes (B). Helper T cells and cytotoxic T cells are recognized, respectively, by the expression of 
CD3 and CD4 (C) or CD3 and CD8 (D) surface markers inside the lymphocyte gate. 
 
The results relative to the frequency of T cells and their two major compartments are 
displayed in Figure 4.2. In the MPS II and MPS VI patient groups, the percentages of total T cells 
(Figure 4.2–A), CD4+ helper T cells (Figure 4.2–B), and CD8+ cytotoxic T cells (Figure 4.2–C) are 
normal when comparing with the group of control subjects. Surprisingly, an increase of the CD4+ 
T cell subset (Figure 4.2–B) is observed in the case of MPS VI patients (p=0.0333) in comparison 
with MPS II patients. 
 
 
 
 
 
A B 
C D 
47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. T cell and T cell subset frequency in MPS II and MPS VI patients. Frequency of (A) total 
T cells, (B) CD4+ T cells in total lymphocytes, and (C) CD8+ T cells in total lymphocytes. Dark blue 
circles represent cell frequency in MPS II patients under ERT; light blue circles represent cell 
frequency in untreated MPS II patients; red circles represent cell frequency in MPS VI patients under 
ERT; green squares represent cell frequency in control subjects; horizontal bars represent mean 
values. *p<0.05. 
 
Further characterization of the T cell population was performed through analysis of the 
naïve (CD45RA+CCR7+), effector memory (CCR7–), and central memory (CD45RA–CCR7+) 
phenotypes in both CD4+ and CD8+ T cell compartments. A total of five MPS II patients, all MPS VI 
patients, and all control subjects were studied by flow cytometry for these parameters. 
The results regarding the frequency of naïve, effector memory (EM), and central memory 
(CM) CD4+ helper T cells and CD8+ cytotoxic T cells are represented in Figure 4.3. MPS II patients 
show no differences in the percentage of naïve (Figure 4.3–A,D), effector memory (Figure 4.3–
B,E), and central memory (Figure 4.3–C,F) subsets in both CD4+ and CD8+ T cell populations as 
compared with control subjects. In the case of MPS VI patients, significant increases of naïve CD4+ 
T cells (p=0.0029) (Figure 4.3–A) and naïve CD8+ T cells (p=0.0037) (Figure 4.3–D), with 
concomitant alterations of the memory phenotypes in both CD4+ and CD8+ T cells, are seen when 
comparing with the control group. In particular, significant decreases of central memory CD4+ T 
cells (p=0.0004) (Figure 4.3–C) and effector memory CD8+ T cells (p=0.03) (Figure 4.3–E) are 
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identified in these patients, with normal levels of effector memory CD4+ T cells (Figure 4.3–B) and 
central memory CD8+ T cells (Figure 4.3–F) being found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Naïve, effector memory, and central memory T cell subset frequency in MPS II and 
MPS VI patients. Frequency of (A) naïve cells in CD4+ T cells, (B) effector memory cells in CD4+ T 
cells, (C) central memory cells in CD4+ T cells, (D) naïve cells in CD8+ T cells, (E) effector memory cells 
in CD8+ T cells, and (F) central memory cells in CD8+ T cells. Dark blue circles represent cell frequency 
in MPS II patients under ERT; red circles represent cell frequency in MPS VI patients under ERT; green 
squares represent cell frequency in control subjects; horizontal bars represent mean values. *p<0.05; 
**p<0.01; ***p<0.001. 
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4.3. NK cell frequency in MPS II and MPS VI patients 
 
NK cells are part of the innate immune system. In this work, NK cells (CD3–CD56+ cells) 
were also analyzed in six MPS II patients, all MPS VI patients, and all control subjects. The gating 
strategy used to recognize NK cells by flow cytometry is shown in Figure 4.4. 
 
 
 
 
 
 
 
 
Figure 4.4. Flow cytometry analysis of NK cells. A lymphocyte gate is firstly established in a forward 
scatter and side scatter cytogram (A) and NK cells are then selected as CD3–CD56+ cells (B). 
 
The results regarding the NK cell frequency are displayed in Figure 4.5. A significant 
decrease of the levels of NK cells is observed in MPS VI patients (p=0.0107) in comparison with 
control subjects, but no alterations are detected in MPS II patients or between the two patient 
groups.  
 
 
 
 
 
 
 
Figure 4.5. NK cell frequency in MPS II and MPS VI patients. Dark blue circles represent cell 
frequency in MPS II patients under ERT; red circles represent cell frequency in MPS VI patients under 
ERT; green squares represent cell frequency in control subjects; horizontal bars represent mean 
values. *p<0.05. 
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4.4. iNKT cell and iNKT cell subset frequency in MPS II and MPS VI patients 
 
iNKT cells are involved in the recognition of lipid antigens and play a role in both innate 
and adaptive immunity, sharing diverse characteristics with T cells and NK cells. In this study, the 
percentage of iNKT cells (CD3+ PBS57-loaded hCD1d tetramer+ cells) was assessed in nine MPS II 
patients, all MPS VI patients, and all control subjects. Their three major subpopulations – iNKT 
CD4+ cells (CD4+CD8– iNKT cells), iNKT CD8+ cells (CD4–CD8+ iNKT cells), and iNKT double-        
-negative cells (CD4–CD8– iNKT cells) – were also studied in eight MPS II patients as well as all 
MPS VI patients and control subjects. The gating strategy used to identify iNKT cells and their 
subsets by flow cytometry is described in Figure 4.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Flow cytometry analysis of iNKT cells and iNKT cell subsets. Upon definition of a 
lymphocyte gate in a forward scatter and side scatter cytogram (A), a second gate comprising CD3+ 
cells is selected (B), after which iNKT cells are identified by the expression of both CD3 marker and 
PBS57-loaded hCD1d tetramer (C). The subpopulations of iNKT CD4+ cells, iNKT CD8+ cells, and iNKT 
double-negative cells are then distinguished according to CD4 and CD8 differential expression (D). 
A B 
C D 
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The results relative to the frequency of iNKT cells and their compartments are presented 
in Figure 4.7. No differences in the iNKT cell percentage among total T cells are found between 
MPS II or MPS VI patients and control subjects or when comparing the two patient groups (Figure 
4.7–A). In a similar way, both MPS II and MPS VI patients show normal levels of iNKT CD4+ cells 
(Figure 4.7–B), iNKT CD8+ cells (Figure 4.7–C), and also iNKT double-negative (DN) cells (Figure 
4.7–D) as compared with the control group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. iNKT cell and iNKT cell subset frequency in MPS II and MPS VI patients. Frequency of 
(A) iNKT cells in total T cells, (B) CD4+CD8– cells in iNKT cells, (C) CD4–CD8+ cells in iNKT cells, and 
(D) CD4–CD8– cells in iNKT cells. Dark blue circles represent cell frequency in MPS II patients under 
ERT; the light blue circle represents cell frequency in the untreated MPS II patient; red circles 
represent cell frequency in MPS VI patients under ERT; green squares represent cell frequency in 
control subjects; horizontal bars represent mean values. 
 
To further characterize the iNKT cells, the expression of the NK cell marker CD161 was 
analyzed by flow cytometry in six MPS II patients, all MPS VI patients, and twenty-six control 
subjects. 
As shown in Figure 4.8, a significant decrease in the frequency of CD161-expressing iNKT 
cells is identified in MPS II patients (p=0.0364) and MPS VI patients (p=0.0087) in comparison 
with control subjects. 
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Figure 4.8. CD161-expressing iNKT cell frequency in MPS II and MPS VI patients. Dark blue circles 
represent cell frequency in MPS II patients under ERT; red circles represent cell frequency in MPS VI 
patients under ERT; green squares represent cell frequency in control subjects; horizontal bars 
represent mean values. *p<0.05; **p<0.01. 
 
 
4.5. B cell frequency in MPS II and MPS VI patients 
 
B cells mediate humoral responses of the adaptive immune system through antibody 
secretion, in addition to playing a role in antigen presentation to T cells. In this work, the B cell 
population (CD19+ cells) was studied in all MPS II and MPS VI patients as well as control subjects. 
The gating strategy used to recognize B cells by flow cytometry is represented in Figure 4.9. 
 
 
 
 
 
 
 
 
Figure 4.9. Flow cytometry analysis of B cells. A lymphocyte gate is firstly selected in a forward 
scatter and side scatter cytogram (A), followed by recognition of B cells as CD19-expressing 
lymphocytes (B). 
 
As demonstrated in Figure 4.10, MPS II and MPS VI patients display no alterations in the B 
cell levels between each other or when comparing with the group of control subjects. 
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Figure 4.10. B cell frequency in MPS II and MPS VI patients. Dark blue circles represent cell 
frequency in MPS II patients under ERT; light blue circles represent cell frequency in untreated MPS II 
patients; red circles represent cell frequency in MPS VI patients under ERT; green squares represent 
cell frequency in control subjects; horizontal bars represent mean values. 
 
 
4.6. Monocyte frequency in MPS II and MPS VI patients 
 
Monocytes are innate immune cells important for the normal T cell function through the 
presentation of antigens. In this study, the percentage of monocytes was assessed in six MPS II 
patients, fourteen MPS VI patients, and twenty-six control subjects. The gating strategy used to 
identify monocytes by flow cytometry is shown in Figure 4.11. 
 
 
 
 
 
 
 
 
 
Figure 4.11. Flow cytometry analysis of monocytes. A gate comprising both lymphocytes and 
monocytes is firstly created in a forward scatter and side scatter cytogram (A), from which monocytes 
are then selected (B). 
 
The results relative to the monocyte frequency are presented in Figure 4.12. Although 
normal levels are found between MPS II patients and control subjects or when comparing the two 
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patient groups, a significant decrease in the percentage of monocytes is observed in MPS VI 
patients (p=0.0305) as compared with control subjects.  
 
 
 
 
 
 
 
Figure 4.12. Monocyte frequency in MPS II and MPS VI patients. Dark blue circles represent cell 
frequency in MPS II patients under ERT; red circles represent cell frequency in MPS VI patients under 
ERT; green squares represent cell frequency in control subjects; horizontal bars represent mean 
values. *p<0.05. 
 
 
4.7. Longitudinal study in MPS VI patients 
 
The frequency of various peripheral blood leukocyte populations, namely B cells, T cells 
and their two major compartments, as well as iNKT cells, was evaluated twice, in 2012/2013 and 
2015, in a total of ten MPS VI patients. 
The results of this longitudinal study are displayed in Figure 4.13. There is a tendency 
toward a decrease in the percentage of B cells and also a trend to an increase in the levels of T 
cells in MPS VI patients between the two analyses. Apart from that, no significant alterations 
during the period between 2012/2013 and 2015 are demonstrated in regards to the CD4+ and 
CD8+ T cell subsets, wherein the evolution of their frequency is highly variable among the MPS VI 
patients, as well as in the case of iNKT cell percentage, whose values show certain stability in this 
group. 
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Figure 4.13. Longitudinal study of the frequency of B cells, T cells, T cell subsets, and iNKT cells 
in MPS VI patients. Evolution of the frequency of (A) B cells, (B) T cells, (C) CD4+ T cells in total 
lymphocytes, (D) CD8+ T cells in total lymphocytes, and (E) iNKT cells in total T cells in 2012/2013 
and 2015 in MPS VI patients. 
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5. CHAPTER I – DISCUSSION 
 
The lysosome plays a crucial role in many immune processes (e.g. antigen presentation), 
thus being important for the normal function of immune cells. The intralysosomal accumulation of 
non-degraded or partially digested macromolecular substrates that occurs in LSDs led, therefore, 
to the hypothesis that the immune system may potentially be altered in these diseases, either as a 
result of impairment of the protective immune cell processes against invading organisms or, 
alternatively, owing to disruption of the biology of immune cells affected by lysosomal storage. In 
line with this, alterations in different leukocyte populations were already reported in several 
LSDs; however, little is known about the immunological abnormalities in the MPS disorders, with 
studies in murine models and especially in humans remaining scarce up until this moment. 
Herein, we analyzed the frequency of T cells and their subsets, B cells, NK cells, and 
monocytes in the peripheral blood of MPS II and MPS VI patients, with the main purpose of 
characterizing the immune system in these two diseases. The results of this study, with emphasis 
on the imbalances identified between MPS II or MPS VI patients and control subjects, are summed 
up in Table 5.1. 
 
Table 5.1. Results of the analysis of the immune system in MPS II and MPS VI diseases 
Leukocyte population MPS II MPS VI Control 
T cells 73.7 ± 7.4% 77.1 ± 5.8% 72.8 ± 8.8% 
CD4+ T cells 38.4 ± 8.1% 46.7 ± 8.2% 41.6 ± 8.5% 
Naïve CD4+ T cells 53.4 ± 14.7% 65.9 ± 11.4% 50.3 ±12.5% 
EM CD4+ T cells 20.2 ± 7.2% 15.4 ± 8.1% 20.4 ± 9.4% 
CM CD4+ T cells 24.5 ± 8.6% 16.2 ± 6% 27 ± 10% 
CD8+ T cells 27.4 ± 6.2% 25.2 ± 5.4% 25 ± 5.3% 
Naïve CD8+ T cells 63.7 ± 18.3% 62.8 ± 13.5% 48.1 ± 13.2% 
EM CD8+ T cells 30.9 ± 15.5% 33 ± 11.3% 44.2 ± 17.1% 
CM CD8+ T cells 3.8 ± 2.1% 3.1 ± 2.8% 6.6 ± 12.7% 
iNKT cells 0.17 ± 0.28% 0.09 ± 0.09% 0.16 ± 0.19% 
iNKT CD4+ cells 40.6 ± 22.3% 38.4 ± 18.3% 38.1 ± 20.7% 
iNKT CD8+ cells 27.2 ± 21.7% 13.2 ± 10.8% 17.5 ± 15.1% 
iNKT DN cells 31.7 ± 13.7% 45.5 ± 18.2% 43.1 ± 14.8% 
iNKT CD161+ cells 62.7 ± 24.1% 75.4 ± 13.6% 87.1 ± 11.1% 
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Table 5.1. Results of the analysis of the immune system in MPS II and MPS VI diseases 
(cont.) 
Leukocyte population MPS II MPS VI Control 
B cells 12.1 ± 9.2% 12.1 ± 5% 9 ± 3.3% 
NK cells 12.7 ± 4.5% 9.6 ± 3.9% 16 ± 8.5% 
Monocytes 7.8 ± 5.7% 4.2 ± 3.2% 7.4 ± 4.3% 
EM: effector memory; CM: central memory; DN: double-negative. 
: increase of cell frequency as compared with control subjects. 
: decrease of cell frequency in comparison with control subjects. 
 
 
 
5.1. T cell, B cell, NK cell, and monocyte frequency in MPS II and MPS VI patients 
 
In the analysis of the percentage of the major peripheral blood leukocyte populations, 
MPS II and MPS VI patients showed normal T cell and B cell levels in comparison with control 
subjects, and also no differences were found between the two patient groups. The frequency of T 
cells was already evaluated and described as normal in other human LSDs, namely Fabry disease 
[36] and Niemann-Pick disease type C1 [45]. Similar results regarding the B cell percentage were 
previously reported in Gaucher disease [84] and Niemann-Pick disease type C1 [45] patients. In 
Fabry disease, however, an increase of B cells was demonstrated [40]. A prior work conducted in 
our laboratory did also identify higher B cell levels in MPS VI patients comparing with the control 
group [49], but the same result was not observed herein. Likely explanations for this discrepancy 
are that a larger number of MPS VI patients as well as age-matched control subjects were included 
in the present study, which was not possible to accomplish during the primary work carried out in 
the laboratory. 
The two untreated MPS II patients that participated in this study were analyzed for the 
frequency of circulating T cell and B cell populations. Despite the fact that both individuals 
presented a T cell percentage near the mean value of the MPS II patient group, they also 
registered the two lowest B cell levels. This finding, along with the previous demonstration of the 
existence of disease-specific intralysosomal storage substances in B cells from MPS II patients 
[32], raises the question of whether ERT may have an effect on immune cell numbers, particularly 
on B cells. 
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On the other hand, in this work, a significant decrease in the frequency of NK cells and 
monocytes was uncovered in MPS VI patients as compared with control subjects. This defect 
appeared to be disease-specific since MPS II patients showed normal levels of both leukocyte 
populations, which led to the hypothesis that the causative mutation(s) of the LSD disorder or the 
lysosomal storage compound(s) might have an influence on these results. In line with this, several 
authors already documented alterations in these groups of immune cells in the context of other 
human LSDs. A decreased NK cell percentage was identified in Niemann-Pick disease type C1 [45] 
and Gaucher disease [84], but not in Fabry disease [40] patients. Monocytes were also shown to 
be reduced in Gaucher disease [85] and Fabry disease [40]. In accordance with the findings of our 
study, a prior report described a normal frequency of NK cells in MPS II patients [31]. The 
presence of disease-specific intralysosomal storage material was previously reported in 
monocytes from MPS VI patients [34]; thus, it is possible that a toxic effect of the accumulated 
GAG substrate – dermatan sulfate – conduces to significant cell morphology and function 
impairment, culminating in a higher apoptotic rate of these immune cells. Overall, the fact that the 
alterations in the peripheral blood levels of NK cells and monocytes are restricted to some LSDs 
suggests that lysosomal accumulation per se does not cause such deficiencies, but there is rather a 
particular negative effect of the compounds that are stored inside the lysosome or, alternatively, 
of the specific genetic mutation(s) leading to these disorders. 
 
 
5.2. T cell subset frequency in MPS II and MPS VI patients 
 
In terms of the frequency of the two major T cell compartments, no differences were 
found in helper CD4+ T cells and cytotoxic CD8+ T cells between each patient group and control 
subjects. Surprisingly, in the present work, an increase of CD4+ T cells was observed in MPS VI 
patients as compared with the MPS II patient group. A previous study carried out in MPS II 
patients revealed no abnormalities in both T cell subpopulations [31], thus being in agreement 
with the results presented herein. Nevertheless, the findings documented in several reports 
relative to other human LSDs are more variable. For instance, normal levels of CD4+ T cells, but a 
decreased percentage of CD8+ T cells, were detected in Fabry disease patients [40]. In the case of 
Gaucher disease, an increase of CD8+ T cells with a concomitant reduction of CD4+ T cells were 
demonstrated [43]. Another study, however, identified no alterations in the two T cell subsets in 
Gaucher disease, but only seven patients were analyzed [84]. The frequency of helper and 
cytotoxic T cells was also evaluated in various MPS murine models, wherein the results showed 
also certain variability among the different disorders. MPS IIIB mice were described to display an 
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increase of both splenic T cell compartments [47], whereas reduced levels of circulating CD4+ and 
CD8+ T cells were observed in MPS I mice [30], but no anomalies concerning these groups of 
immune cells were found in the thymus, spleen, and lymph nodes of MPS VII mice [46]. 
 
Interestingly, despite the normal frequency of the two major T cell subpopulations, the 
analysis of their memory status revealed significant alterations in MPS VI patients, including 
increases of naïve with concomitant decreases of memory CD4+ and CD8+ T cells in comparison 
with control subjects. Importantly, these abnormalities cannot be attributed to age differences 
between the two groups of individuals, given that they were age-matched. Similarly, a study 
performed in the MPS I mouse model did also identify a reduction in the percentage of peripheral 
blood memory CD4+ T cells [30]. In Gaucher disease patients, a reduction of naïve CD4+ T cells 
and an increase of memory CD4+ T cells were already documented, along with normal levels of 
both phenotypes within the CD8+ T cell subset [84]. 
Also in the present work, MPS II patients did not show anomalies in the memory state of 
both helper and cytotoxic T cells when comparing with control subjects. Although these results 
can be explained by the accumulation of different types of substrate inside the lysosome, it is also 
possible that the absence of significant alterations in the MPS II patient group is related to the 
small number of individuals that were analyzed for these parameters in our study (five MPS II 
patients versus sixteen MPS VI patients). 
 
 
5.3. iNKT cell and iNKT cell subset frequency in MPS II and MPS VI patients 
 
The analysis of the iNKT cell percentage within the T cell population demonstrated no 
differences between MPS II and MPS VI patients or when comparing each patient group with 
control subjects. In a similar way, normal iNKT cell levels were described in previous studies 
carried out in Fabry disease [36,40,41], Gaucher disease [43], and Niemann-Pick disease type C1 
[44] patients. Given that the frequency of iNKT cells in the peripheral blood is highly variable 
among the general human population, the detection of smaller alterations between patients and 
healthy subjects may be difficult to accomplish. 
Although both untreated MPS II patients included in this work were also analyzed for this 
parameter by flow cytometry, it was only possible to assess the percentage of iNKT cells in one of 
them, due to the corresponding reduced number of events that were acquired from the sample of 
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the second individual. In the case of the untreated patient for whom the iNKT cell levels were 
determined, one of the lowest values in the MPS II patient group was observed. Even though it 
was not possible to evaluate the effect of ERT on the iNKT cell frequency in MPS II patients, owing 
to the limited availability of untreated patients that could be included in our study, ERT was 
already shown to partially correct a deficiency of iNKT cells found in the Fabry disease mouse 
model [86]. In that report, ERT caused not only a decrease in the intralysosomal storage of 
macromolecular substrate in the spleen and liver of Fabry disease mice, but also an increase in the 
frequency of splenic iNKT cells, in particular of the iNKT CD4+ cell subset, thus preventing the 
reduction in iNKT cell levels that occurs with age in untreated mice [86]. 
 
Furthermore, in the present work, the percentage of iNKT cells expressing CD4, CD8, or 
none of the surface markers was not significantly altered in MPS II and MPS VI patients as 
compared with control subjects or between the two patient groups. Despite the absence of 
abnormalities in the frequency of total iNKT cells, a prior study conducted in Fabry disease 
patients demonstrated alterations in the composition of iNKT cell compartments, including an 
increase of iNKT double-negative cells with a concomitant reduction of iNKT CD4+ cells [41]. In 
agreement with the results reported herein, no differences were detected in Niemann-Pick 
disease type C1 patients with respect to the CD4 and CD8 status of the iNKT cell population [44]. 
 
Interestingly, both groups of MPS II and MPS VI patients presented a decrease in the 
expression of the NK cell marker CD161 in iNKT cells when comparing with control subjects. On 
the contrary, normal levels of CD161-expressing iNKT cells were documented in Niemann-Pick 
disease type C1 patients [44]. 
 
 
5.4. Longitudinal study in MPS VI patients 
 
Ten out of sixteen MPS VI patients under ERT were analyzed twice over a period of 2–3 
years with respect to the frequency of T cells and their two major subpopulations, as well as B 
cells and iNKT cells. 
 
Between these two determinations, an overall slight increase of T cells was observed in 
eight MPS VI patients. This, however, does not appear to be associated with a specific T cell 
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compartment, since some patients displayed predominantly an increment of CD4+ helper T cell 
levels whereas others presented mostly an increased percentage of CD8+ cytotoxic T cells. 
Previous studies described that the relative frequency of T cells within the lymphocyte population 
shows certain stability from the first months of life until early adulthood, ranging between median 
narrow limits of 62–73% in healthy human subjects [87,88]. Similarly, the percentage of the CD4+ 
and CD8+ T cell subsets tends to vary slightly with age, with mean values oscillating from 35% to 
55% and from 16% to 28%, respectively [87,88]. Therefore, the small increase of T cell levels 
identified in MPS VI patients between 2012/2013 and 2015, as well as the variations detected in 
CD4+ and CD8+ T cells are within the standard value ranges and can be considered as normal 
limited fluctuations that are typically registered over time, from neonates until young adults. 
 
In regards to the evolution of B cell frequency, a tendency toward a decrease between the 
two analyses was detected in eight MPS VI patients. Interestingly, the only two cases wherein B 
cell levels increased over time – MPS VI patients #5 and #13 – correspond also to both individuals 
whose percentage of T cells was exceptionally reduced. Age-associated alterations in the B cell 
population were already described in healthy human subjects, in which the relative frequency of B 
cells generally duplicates from a median of 12% to 24% during the first months of life, then 
stabilizes until 5 years of age, after which a gradual decrease to approximately 13–15% occurs 
until early in adult life [87,88]. Although lower levels of B cells were reported in the present work, 
the slight reduction herein identified in this cellular compartment constitutes an expected result 
considering that most MPS VI patients were analyzed in the period between adolescence and 
young adulthood. 
 
With respect to the percentage of iNKT cells within the total T cell population, MPS VI 
patients showed relatively similar values in 2012/2013 and 2015. In agreement with these 
findings, prior longitudinal studies carried out in MPS VI [49] and Fabry disease [89] patients 
under ERT also documented the absence of significant alterations in the iNKT cell frequency over 
time. A previous report, however, described a slight increase of iNKT cells with age in healthy 
young individuals [90]. Nevertheless, the interpretation of such results is hampered by the wide 
variability of iNKT cell levels in human peripheral blood. 
 
The fact that all MPS VI patients included in this study were already under ERT for several 
years at the time that the first analysis was performed in our laboratory, together with the 
findings that they presented normal variations in the levels of immune cell populations that are 
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associated with increasing age, raises the question of whether ERT may have an influence on 
these results. Therefore, the longitudinal analysis of untreated MPS VI patients would be crucial to 
answer this question. 
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CHAPTER II 
PRODUCTION AND CHARACTERIZATION OF 
EBV-TRANSFORMED B CELL LINES FROM 
MPS II AND MPS VI PATIENTS 
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6. CHAPTER II – RESULTS 
 
In the study concerning the generation and phenotypic characterization of EBV-                   
-transformed B cell lines that was developed during the period of my thesis, I implemented the 
respective protocols in the laboratory, executed all the experimental activities, and performed the 
analysis of all the results presented hereafter in this chapter. 
 
 
6.1. MPS patients and control subject characteristics 
 
For the production of EBV-transformed B cell lines, five male MPS II patients with a mean 
age of 13 ± 3.4 years (range: 9–17 years) and five MPS VI patients with a mean age of 15.2 ± 4.7 
years (range: 8–21 years), which comprised one female and four males, were analyzed. 
The control group, on the other hand, was composed of nine apparently healthy adult 
subjects, including six females and three males, with a mean age of 32 ± 5.2 years (range: 26–41 
years). 
 
 
6.2. Efficacy in the production of EBV-transformed B cell lines from MPS II and MPS 
VI patients 
 
Before the generation of EBV-transformed B cell lines from MPS II and MPS VI patients, a 
preliminary work was conducted to produce EBV virions and implement in our laboratory the 
protocol for the transformation of human B cells by EBV; this implementation was based on 
standard protocols [91–93]. This primary work allowed the optimization of some experimental 
conditions, such as the optimal amount of EBV-containing supernatant that should be used 
according to the stock of EBV virions that was produced, the proper concentration of cyclosporine 
A, and the minimum time necessary for the formation of large cell aggregates. 
 
To induce B cell transformation in vitro, PBMCs isolated from peripheral blood samples 
were incubated with EBV virions and, after a period of 35 days of culture that enabled sufficient 
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cell growth, infected cells were analyzed by flow cytometry. From a total of nineteen individuals 
for whom this protocol was applied, the production of EBV-transformed B cell lines was 
successful in all but one of those cases. In the case wherein the B cell transformation failed, the 
number of PBMCs available for the process of EBV infection was very low (1x106 PBMCs); this 
was the case of MPS II patient #9, in which a marked decrease in cell number occurred during the 
first two weeks after infection, rather than the expansion of cells into actively proliferating 
cultures. 
 
The development of EBV-transformed B cell lines was regularly monitored, being 
documented through weekly photographs, until day 35 post-infection, when cryopreservation and 
phenotypic characterization were performed. According to what has been described, small 
clusters of infected B cells in suspension are generally visible under the microscope within the 
first week of culture, which typically exhibit rosette morphology and are composed of cells with 
increased size [78,92,94], as demonstrated in Figure 6.1. Between the days 14 and 21 after 
infection, the growth of microscopic colonies usually starts to evolve exponentially and, as time 
progresses, large cell clumps become visible macroscopically [92,94]. 
 
 
Figure 6.1. EBV-infected B cell clusters. Microscopic appearance on (A) day 7 post-infection, (B) day 
21 post-infection, and (C) day 35 post-infection. EBV-transformed B cell aggregates are identified by 
the arrows. Magnification: 400x. 
 
Based on the weekly microscopic observation of cell cultures from control subjects, the 
growth rate of infected cells revealed high variability between individuals, particularly since the 
third week of culture. In general, the evolution of cell clusters was similar between the various 
cultures until day 21 post-infection; from this moment, however, while some cultures exhibited an 
exponential proliferation, others were more slowly progressing. This was assessed by the size and 
A B C 
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number of cell aggregates, as shown in Figure 6.2, and also by taking into account the frequency 
with which the medium needed to be changed and the culture splitting had to be performed. In 
three cultures whose development was less pronounced since the third week after infection, the 
presence of adherent cells may have slowed down the growth of cell clusters. Even though it 
partially increased after several changes of cell clumps in suspension into new wells of the culture 
plate, these cell aggregates did not reach the same proliferative capacity until day 35 post-               
-infection as observed in the cultures wherein there were no adherent cells. 
 
 
Figure 6.2. Growth progression of EBV-transformed B cell lines from two control subjects. 
Microscopic appearance on (A) day 7 post-infection, (B) day 21 post-infection, and (C) day 35 post-              
-infection. Dark agglomerates represent clusters of EBV-infected B cells. Magnification: 40x. 
 
In the case of all four MPS II patients, the development of cell clusters was initially 
hampered after the appearing of many adherent cells, typically during the second or third weeks 
upon infection. The presence of such large number of adherent cells in the culture was always 
A B C 
A B C 
Rapidly progressing EBV-transformed B cell line from a control subject 
Slowly progressing EBV-transformed B cell line from a control subject 
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associated with a lower proliferation rate of the infected cells. Even so, the growth of cell 
aggregates was, in general, recovered after applying the same technique of successive changes of 
cells in suspension into new wells of the culture plate, although not with the same degree in all 
cultures. In this way, some exhibited a significant improvement of their development, as 
evidenced by increased splitting and changes of the medium, as well as the size and number of cell 
clumps; in contrast, other cultures did not follow the same positive growth evolution until day 35 
post-infection, as represented in Figure 6.3. When comparing MPS II patients with control 
subjects, the variability registered in the global proliferation of cell cultures – in which some were 
slowly progressing and others actively proliferating – seems to indicate similar outcomes in these 
two groups in regards to the production of EBV-transformed B cell lines. 
 
 
Figure 6.3. Growth progression of EBV-transformed B cell lines from two MPS II patients. 
Microscopic appearance on (A) day 7 post-infection, (B) day 21 post-infection, and (C) day 35 post-              
-infection. Dark agglomerates represent clusters of EBV-infected B cells. Magnification: 40x. 
 
A B C 
A B C 
Rapidly progressing EBV-transformed B cell line from a MPS II patient 
Slowly progressing EBV-transformed B cell line from a MPS II patient 
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In the group of MPS VI patients, a total of four out of five cell cultures presented a higher 
growth rate than in the overall cases of MPS II patients and control subjects, considering not only 
the presence of many large cell colonies clearly observed since the third week after infection, but 
also the number of times that the cultures had to be splitted due to increased cell density. The 
exceptional case was MPS VI patient #6, in which the initial development of cell clusters was 
significantly hindered in the presence of many adherent cells in the culture. Even though the 
procedure of transferring the cell aggregates in suspension into new wells of the culture plate was 
also applied, the growth of infected cells did not register a great improvement until day 35 post-    
-infection, as evidenced by the reduced frequency with which the medium had to be changed. The 
evolution of the growth of an EBV-transformed B cell line from one of these four MPS VI patients, 
whose production was achieved without registering any problem, as well as of the EBV-                    
-transformed B cell line from MPS VI patient #6 is shown in Figure 6.4. 
 
 
Figure 6.4. Growth progression of EBV-transformed B cell lines from two MPS VI patients. 
Microscopic appearance on (A) day 7 post-infection, (B) day 21 post-infection, and (C) day 35 post-              
-infection. Dark agglomerates represent clusters of EBV-infected B cells. Magnification: 40x. 
A B C 
A B C 
Rapidly progressing EBV-transformed B cell line from a MPS VI patient 
Slowly progressing EBV-transformed B cell line from MPS VI patient #6 
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In addition to the regular monitoring of their development, the successful generation of 
EBV-transformed B cell lines was tested by thawing the cryopreserved cells from one MPS VI 
patient as well as one control subject and putting them back in culture during one week. The 
results confirmed the cell viability and the high proliferation rate of EBV-transformed B cell lines. 
 
The efficacy in the production of EBV-transformed B cell lines was also evaluated by 
taking into consideration the B cell percentage before and after viral transformation. A first 
determination of the frequency of B cells, identified as CD19+ lymphocytes, was performed by 
flow cytometry using PBMCs prior to incubation with EBV. A second flow cytometry analysis was 
carried out using EBV-infected cells after 35 days of culture. Both parameters were assessed in all 
individuals for whom the EBV-transformed B cell lines were successfully generated. However, in 
the case of the first control subject analyzed in this work, the intensity of the fluorescence signal 
of CD19+ cells in the EBV-transformed B cell line sample, which were exceptionally stained with 
fluorescein isothiocyanate (FITC)-labelled anti-human CD19 antibody, was very low; thus, the 
data from control subject #1 will not be considered in the following analyses. 
The results concerning the B cell frequency within PBMCs prior to viral transformation 
(day 0, D0) and in EBV-transformed B cell lines following 35 days of culture (day 35, D35) are 
presented in Figure 6.5. As described in Chapter I, MPS II and MPS VI patients do not show 
alterations in the B cell population in comparison with control subjects. In both patient groups for 
whom the EBV-transformed B cell lines were produced, normal B cell levels are also detected 
before EBV infection (Figure 6.5–A), being in accordance with the previous result. 
Similarly, no differences in the frequency of B cells in EBV-transformed B cell lines are 
observed when MPS II and MPS VI patients are compared with control subjects or between the 
two patient groups (Figure 6.5–B). Surprisingly, for three control subjects, the percentage of B 
cells upon viral transformation is less than 50%, despite the general similar appearance, although 
exhibiting smaller cell clusters, of the infected cell cultures from these individuals comparing with 
those from the remaining control subjects. 
As expected, the B cell frequency increases after EBV-induced transformation when 
compared with the corresponding samples of PBMCs before viral infection (p=0.0286, p=0.0079, 
and p=0.0006 in the groups of MPS II patients, MPS VI patients, and control subjects, respectively) 
(Figure 6.5–C), thus confirming the global successful generation of EBV-transformed B cell lines. 
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Figure 6.5. B cell frequency before and after EBV-induced transformation of B cells in MPS II 
and MPS VI patients. (A) B cell frequency before viral transformation; (B) B cell frequency after viral 
transformation; (C) Comparison between the B cell frequency before (D0) and after (D35) viral 
transformation. Dark blue circles represent cell frequency in MPS II patients under ERT; the light blue 
circle represents cell frequency in the untreated MPS II patient; red circles represent cell frequency in 
MPS VI patients under ERT; green squares represent cell frequency in control subjects; horizontal and 
vertical bars represent mean values. *p<0.05; **p<0.01; ***p<0.001. 
 
To investigate whether the B cell percentage prior to the transformation process may 
have any influence on the levels of B cells obtained after producing the EBV-transformed B cell 
lines, the evolution of B cell frequency between day 0 (D0) and day 35 post-infection (D35) was 
analyzed for each individual. 
The results shown in Figure 6.6 indicate that the efficacy in the generation of EBV-               
-transformed B cell lines cannot be predicted based on the percentage of B cells within the PBMC 
samples used for viral infection. This can be demonstrated, for instance, by the cases of MPS II 
patient #7 (Figure 6.6–A) and control subject #7 (Figure 6.6–C), in which both individuals display 
similar B cell levels on day 0 (8.6% and 8.2%, respectively), but clearly present different 
outcomes with respect to the frequency of B cells after viral transformation (92% and 18.8%, 
respectively). 
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Figure 6.6. Evolution of B cell frequency before and after EBV-induced transformation of B cells 
in MPS II and MPS VI patients. Evolution of B cell frequency in (A) MPS II patients, (B) MPS VI 
patients, and (C) control subjects before (D0) and after (D35) viral transformation. 
 
To further assess the efficacy in the production of EBV-transformed B cell lines, the ratio 
of B cell expansion was calculated by dividing the number of B cells in culture on day 35 after 
infection by the number of B cells that were initially infected by EBV. 
According to the results represented in Figure 6.7, it is evident that, in the three groups, 
there is a considerable expansion of the original B cell population owing to the generation of EBV-
-transformed B cell lines. As expected taking into account the microscopic observation of the 
growth of cell cultures, the MPS VI patient group exhibits the greatest increase in the number of B 
cells acquired after the transformation process (mean ratio: 35.1 ± 27.8), while the groups of MPS 
II patients and control subjects register a similar, although slightly lower, progress (mean ratios: 
11.2 ± 10.8 and 17.8 ± 26, respectively). In all groups, there are one or more cases wherein the B 
cell expansion between day 0 and day 35 post-infection is less pronounced, which correspond to 
the cultures of infected cells whose proliferation was affected after the appearing of adherent 
cells. Of these, the cases of two control subjects, in which the ratio of B cell numbers between the 
two time points is lower than 1, reflect the difficulty in the development of EBV-transformed B cell 
lines from these individuals, related with the presence of adherent cells in the culture. Despite the 
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low number of B cells that was obtained, the cultures from these two control subjects showed 
signs of B cell transformation, although there were clearly less and smaller cell clusters on day 35 
upon infection when compared with the cultures wherein no adherent cells emerged. 
 
 
 
 
 
 
 
Figure 6.7. B cell expansion after EBV-induced transformation of B cells in MPS II and MPS VI 
patients. Dark blue circles represent B cell number ratio in MPS II patients under ERT; the light blue 
circle represents B cell number ratio in the untreated MPS II patient; red circles represent B cell 
number ratio in MPS VI patients under ERT; green squares represent B cell number ratio in control 
subjects; horizontal bars represent mean values. 
 
The frequency of B cells before EBV-mediated transformation was correlated with the 
ratio of B cell expansion between day 0 and day 35 post-infection. In all groups, no significant 
correlations were found between the two parameters (Spearman correlation coefficients: r=–1, 
r=0.6, and r=–0.64 in MPS II patients, MPS VI patients, and control subjects, respectively). These 
results confirm that the B cell percentage in PBMC samples used in EBV infection does not predict 
and is not a determinant factor of the growth evolution of EBV-transformed B cell lines. 
 
 
6.3. Phenotype of EBV-transformed B cell lines from MPS II and MPS VI patients 
 
Following 35 days of culture of the infected B cells, the phenotypic characterization of 
EBV-transformed B cell lines was performed by flow cytometry. For this purpose, four 
phenotypes were defined based on the differential expression of IgM and CD27 surface markers in 
CD19+ B cells: naïve (IgM+CD27–), IgM memory (IgM+CD27+), double-negative memory (IgM–
CD27–), and switched memory (IgM–CD27+) B cells. This analysis was carried out in two MPS II 
patients, three MPS VI patients, and four control subjects. The gating strategy used to identify the 
B cell subsets by flow cytometry is represented in Figure 6.8. 
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Figure 6.8. Flow cytometry analysis of B cell subsets. A gate comprising viable cells is firstly defined 
in a forward scatter and side scatter cytogram (A), after which B cells are recognized as CD19+ cells 
(B). B cell subsets are then distinguished according to IgM and CD27 differential expression within the 
B cell gate (C). 
 
The results regarding the relative frequency of each B cell subpopulation in the EBV-          
-transformed B cell lines are displayed in Figure 6.9. In all groups, the predominant phenotype of 
EBV-transformed B cells is that corresponding to double-negative (DN) memory B cells, whose 
percentage is especially high in MPS VI patients (mean value: 63.6 ± 10.1%), followed by MPS II 
patients (mean value: 55.4 ± 7.8%) and control subjects (mean value: 44 ± 23.1%) (Figure 6.9–C). 
With respect to the other phenotypes that characterize the EBV-transformed B cell lines, naïve B 
cells constitute the second subset more frequent in the three groups (Figure 6.9–A), with IgM 
memory B cells (Figure 6.9–B) and switched memory B cells (Figure 6.9–D) presenting lower 
levels. As expected, no alterations are identified in the EBV-transformed B cell lines between the 
two patient groups or when comparing MPS II and MPS VI patients with control subjects, in 
relation to the percentage of the various B cell subpopulations. 
 
A B 
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Figure 6.9. B cell subset frequency in EBV-transformed B cell lines from MPS II and MPS VI 
patients. Frequency of (A) naïve B cells, (B)  IgM memory B cells, (C) double-negative memory B cells, 
and (D) switched memory B cells after viral transformation. The dark blue circle represents cell 
frequency in the MPS II patient under ERT; the light blue circle represents cell frequency in the 
untreated MPS II patient; red circles represent cell frequency in MPS VI patients under ERT; green 
squares represent cell frequency in control subjects; horizontal bars represent mean values. 
 
The B cell subsets within PBMCs were evaluated by flow cytometry prior to EBV infection. 
In addition to the four B cell compartments distinguished according to IgM and CD27 differential 
expression, plasma B cells were also identified as CD138-expressing B cells. These parameters 
were studied in four MPS II patients, all MPS VI patients, and eight control subjects. 
The results concerning the relative frequency of each B cell phenotype in the samples of 
PBMCs before viral transformation are described in Figure 6.10. In the three groups, naïve B cells 
present the highest percentage in the B cell population, showing similar levels between MPS II 
patients (mean value: 62.4 ± 23.3%) and MPS VI patients (mean value: 60.6 ± 12.7%), with 
control subjects displaying slightly lower numbers (mean value: 47.3 ± 19.3%) (Figure 6.10–A). In 
terms of the other B cell subsets, IgM memory B cells (Figure 6.10–B) and switched memory B 
cells (Figure 6.10–D) present intermediary frequencies in all groups, whereas double-negative 
(DN) memory B cells (Figure 6.10–C) and plasma B cells (Figure 6.10–E) are the rarest B cell 
subpopulations, especially the latter which is almost undetectable. As these findings anticipated, 
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there are no significant differences in the various B cell compartments prior to EBV infection 
when comparing each patient group with control subjects or between MPS II and MPS VI patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10. B cell subset frequency before EBV-induced transformation of B cells in MPS II and 
MPS VI patients. Frequency of (A) naïve B cells, (B) IgM memory B cells, (C) double-negative memory 
B cells, (D) switched memory B cells, and (E) plasma B cells before viral transformation. Dark blue 
circles represent cell frequency in MPS II patients under ERT; the light blue circle represents cell 
frequency in the untreated MPS II patient; red circles represent cell frequency in MPS VI patients under 
ERT; green squares represent cell frequency in control subjects; horizontal bars represent mean values. 
 
Finally, to assess if the percentage of each B cell subset could be altered between the two 
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time points due to EBV infection, both analyses were compared within each group. For this 
purpose, only the individuals for whom the two determinations were available were considered: 
two MPS II patients, three MPS VI patients, and four control subjects. 
The results relative to the frequency of B cell subpopulations before (day 0, D0) and after 
(day 35, D35) transformation of B cells are represented in Figure 6.11. A tendency to a decrease of 
naïve B cells (Figure 6.11–A) and IgM memory B cells (Figure 6.11–B) is seen in all groups when 
comparing PBMC samples prior to viral infection with EBV-transformed B cell lines. Also, there is 
clearly a trend toward an increase of double-negative (DN) memory B cells (Figure 6.11–C) after B 
cell transformation, reaching statistical significance in the control group (p=0.0286) which has 
more individuals analyzed. In contrast, no alterations in the levels of switched memory B cells 
(Figure 6.11–D) are observed within each group between the two time points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11. B cell subset frequency before and after EBV-induced transformation of B cells in 
MPS II and MPS VI patients. Comparison of the frequency of (A) naïve B cells, (B) IgM memory B cells, 
(C) double-negative memory B cells, and (D) switched memory B cells before (D0) and after (D35) 
viral transformation. The dark blue circle represents cell frequency in the MPS II patient under ERT; 
the light blue circle represents cell frequency in the untreated MPS II patient; red circles represent cell 
frequency in MPS VI patients under ERT; green squares represent cell frequency in control subjects; 
vertical bars represent mean values. *p<0.05.
N
a
ïv
e
 B
 c
e
ll
s
 (
%
)
0
2 0
4 0
6 0
8 0
( D 0 ) ( D 0 ) ( D 0 )
M P S  II M P S  V I C o n t r o l
( D 3 5 ) ( D 3 5 ) ( D 3 5 )
A
Ig
M
 m
e
m
o
r
y
 B
 c
e
ll
s
 (
%
)
0
1 0
2 0
3 0
4 0
( D 0 ) ( D 0 ) ( D 0 )
M P S  II M P S  V I C o n t r o l
( D 3 5 ) ( D 3 5 ) ( D 3 5 )
B
D
N
 m
e
m
o
r
y
 B
 c
e
ll
s
 (
%
)
0
2 0
4 0
6 0
8 0
1 0 0
*
( D 0 ) ( D 0 ) ( D 0 )
M P S  II M P S  V I C o n t r o l
( D 3 5 ) ( D 3 5 ) ( D 3 5 )
C
S
w
it
c
h
e
d
 m
e
m
o
r
y
 B
 c
e
ll
s
 (
%
)
0
1 0
2 0
3 0
4 0
( D 0 ) ( D 0 ) ( D 0 )
M P S  II M P S  V I C o n t r o l
( D 3 5 ) ( D 3 5 ) ( D 3 5 )
D
  
 D 
 
  II                       ntrol 
             
 PS II                        trol 
( ) ( )    ( ) ( )    ( ) ( ) 
 
  II                       trol 
( ) ( )    ( ) ( )    ( ) ( )  
 PS II                        trol 
( ) ( )    ( ) ( )    ( ) ( ) 
 
 
 
 
 
 
 
 
 
 
Ig
M
 m
e
m
o
ry
 B
 c
e
ll
s 
(%
) 
 
 
 
 
 
 
 
 
 
 
N
a
ïv
e
 B
 c
e
ll
s 
(%
) 
 
 
 
 
 
 
 
 
 
 S
w
it
ch
e
d
 m
e
m
o
ry
 B
 c
e
ll
s 
(%
) 
 
 
 
 
 
 
 
 
 
 
 
 
D
N
 m
e
m
o
ry
 B
 c
e
ll
s 
(%
) * 
80 
 
 
81 
 
7. CHAPTER II – DISCUSSION 
 
In this study, the main aim was to produce EBV-transformed B cell lines from MPS II and 
MPS VI patients. The repeated collection of blood samples from these pediatric patients is not only 
an invasive procedure, but also especially hampered by their disease. Therefore, circulating B 
cells were employed in the generation of EBV-transformed B cell lines with the purpose of 
providing a continuous in vitro source of cells from these MPS patients, which can be applied in 
future immunological, biochemical, and genetic analyses. In this way, this work contributed to the 
preservation of the genetic material from Portuguese MPS II and MPS VI patients, which is now 
available in our laboratory to be used by the national and international scientific communities. 
More specifically, this study was also designed to evaluate the efficacy in the production of 
EBV-transformed B cell lines from the two MPS patient groups. In order to assess this, the EBV-               
-transformed B cell lines from MPS II and MPS VI patients were compared with those from control 
subjects in terms of the growth progression of infected cells over 35 days of culture, as well as the 
estimated number of B cells that were obtained after the transformation process. 
Furthermore, another specific objective of this work was to characterize phenotypically 
the EBV-transformed B cell lines from both groups of MPS patients and compare with the 
phenotypes of the B cell population prior to viral infection. 
 
Of note, the mean age of MPS II and MPS VI patients (13 ± 3.4 years and 15.2 ± 4.7 years, 
respectively) was substantially different from the mean age of control subjects (32 ± 5.2 years). It 
was not possible to include age-matched controls in this study because no approval was obtained 
from the ethical committee of Centro Hospitalar de São João regarding the use of blood donor 
samples to produce EBV-transformed B cell lines. Such consent was given by the ethics 
commission of IBMC, but it was restricted to adult subjects. 
 
 
7.1. Production of EBV-transformed B cell lines from MPS II and MPS VI patients 
 
Eighteen EBV-transformed B cell lines were successfully generated in vitro from a total of 
nineteen individuals included in this study: four were from MPS II patients, five from MPS VI 
patients, and nine from control subjects. The only exception was the MPS II patient #9, in which it 
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was not possible to obtain an exponentially proliferating cell culture from EBV-infected cells. The 
most likely explanation for the failure in the production of an EBV-transformed B cell line in this 
case is related to the fact that the volume of peripheral blood received from this patient was very 
low, thus limiting the number of PBMCs that were isolated and employed in B cell transformation 
(1x106 PBMCs). It should be noted that, for all the other MPS patients, a minimal amount of 2x106 
PBMCs was used to generate EBV-transformed B cell lines. 
 
According to the weekly observation of the growth progression of EBV-transformed B cell 
lines during 35 days of culture, similar outcomes were achieved when comparing MPS II patients 
with control subjects. In both groups, there were some cultures that expanded more actively over 
time, whereas others were relatively more slowly progressing. Also, the appearing of adherent 
cells in the cultures with concomitant slowdown in cell aggregate expansion was a recurrent 
problem in the group of MPS II patients and did also occur in one-third of control subjects. 
On the other hand, the proliferation of the EBV-infected cell cultures from MPS VI patients 
evolved exponentially until day 35 post-infection in the majority of cases, thus registering a higher 
growth rate than that observed in the groups of control subjects and MPS II patients. The 
exceptional case wherein the development of cell clusters did not follow the same exponential 
evolution corresponded to the only case within MPS VI patients in which adherent cells arose in 
the culture. 
In this way, the differences identified between the two patient groups concerning the 
efficacy in the production of EBV-transformed B cell lines appear to be related with the presence 
of adherent cells typically in the cultures from MPS II patients. This hypothesis is supported by 
the fact that the global expansion of the respective cell aggregates was significantly attenuated 
following the emergence of adherent cells and also because an increase of their proliferation rate, 
although with variable degrees among MPS II patients, was seen after the removal of adherent 
cells from the virally infected cell cultures. To accomplish this, a technique commonly applied to T 
cell cultures was performed, which consisted in the transference of cell clusters in suspension into 
new wells of the culture plate, while maintaining the adherent cells in the original well. 
 
Given that the arising of adherent cells occurred not only in the cultures from all four MPS 
II patients, but also in those from one MPS VI patient and three control subjects, this event does 
not seem to be disease-specific or correlated with the health status of individuals. Instead, it may 
be associated with the transformation process, in which the adherent cells could be DCs or 
macrophages activated upon viral infection. It was described that DCs play a role in the priming of 
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both innate and adaptive EBV-specific immune responses [95]. The innate control can be 
mediated through the secretion of IFN-α, IFN-β, and IFN-γ, which prevents the outgrowth of 
infected B cells [96,97]. Moreover, the EBV-encoded small RNAs released from these cells can be 
detected by DCs via the toll-like receptor 3 [97], which respond through the release of IL-12; the 
subsequent NK cell activation results in IFN-γ production and limits EBV-induced B cell 
transformation by delaying viral LMP-1 expression [98]. In turn, DCs were also shown to 
phagocytize dying infected B cells and prime both adaptive CD4+ and CD8+ T cells by presenting 
viral latency antigens via MHC class I and II molecules; consequently, activated EBV-specific T 
cells promote the growth regression of transformed B cells through perforin-granzyme-mediated 
lysis, IFN-γ secretion, and Fas-FasL-induced lysis [99]. 
The actions of DCs during EBV infection may possibly explain the impaired development 
of cell clusters that was observed when adherent cells were present in the cultures produced in 
vitro. Although the immune control primed by DCs is, in general, ultimately executed by NK cells 
and T cells, any protective responses of these cells against EBV were most likely inhibited by the 
immunosuppressive effect of cyclosporine A and, thus, were not responsible for such reversion of 
cell growth. Instead, given that the removal of adherent cells from the cultures conduced, at least 
partially, to an improvement in the expansion of cell aggregates, it is reasonable to think that their 
proliferation was mostly affected by direct actions of DCs, namely the secretion of IFN cytokines. 
Even so, it remains to be elucidated the reason why the appearing of adherent cells did only occur 
in some EBV-infected cell cultures. One hypothesis is that the frequency of DCs or their activity in 
the PBMC samples was higher in those particular cases comparing with the remaining individuals. 
Hence, it would be important to analyze, in the future, the percentage of DCs prior to EBV-induced 
B cell transformation to test this theory. 
 
To evaluate whether EBV-transformed B cells were still viable after they have been frozen 
on day 35 post-infection, as well as if their growth could be negatively affected by the thawing 
process, two cryopreserved EBV-transformed B cell lines from a MPS VI patient and a control 
subject were put back in culture during one week. The results confirmed not only the cell viability, 
but also the maintenance of the high proliferative capacity of EBV-transformed B cell lines, thus 
constituting an important indicator of their successful production in vitro. 
 
Other methods used to assess the efficacy in the generation of EBV-transformed B cell 
lines from MPS II and MPS VI patients consisted in the determination of (i) the B cell frequency in 
PBMC samples before viral infection (day 0) and in EBV-transformed B cell lines after 35 days of 
culture (day 35), as well as (ii) the ratio of B cell expansion between the two time points. When 
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comparing each patient group with control subjects or MPS II with MPS VI patients, no differences 
were found in the levels of B cells before and after EBV-mediated transformation. In contrast, the 
comparative analysis within each group of the B cell percentage between day 0 and day 35 
showed, as expected, a significant increase following viral infection. The successful production of 
EBV-transformed B cell lines was further confirmed by the demonstration that the original B cell 
population was expanded as a result of the transformation process. The greater rise in B cell 
frequency and in variation of B cell numbers between the two time points was observed in MPS VI 
patients, with identical outcomes registered in the two other groups, which is in agreement with 
the microscopic observation that the virally infected cell cultures from MPS VI patients presented, 
in general, a higher proliferation rate than those from control subjects and MPS II patients. 
Surprisingly, both methods revealed that, in all groups, there were one or more cultures 
wherein the B cell expansion was less prominent, which were the ones whose development was 
significantly hampered after the arising of adherent cells. Despite the low number of B cells 
obtained on day 35 post-infection, especially in the case of two control subjects, these cultures 
exhibited signs of B cell transformation upon microscopic observation, including the presence of 
cell clusters with typical rosette morphology. Therefore, it is reasonable to think that, if such EBV-
-transformed B cell lines had been maintained in culture beyond day 35 after infection, the 
growth of cell aggregates might have been fully recovered and the final results would have been 
similar to those obtained for the cultures wherein no adherent cells emerged. 
 
The finding that the percentage of B cells recognized by CD19 expression in the samples of 
EBV-transformed B cell lines was below 100% in all groups raises uncertainties on the identity of 
the cells that did not express this surface marker. Likely explanations for the origin of such CD19– 
cells are that the gate created to select viable cells within the EBV-transformed B cell lines might 
also have included (i) cellular debris (e.g. from NK cells and T cells suppressed by cyclosporine A), 
or (ii) PBMCs other than B cells (e.g. monocytes, DCs) that survived until day 35 post-infection. 
Characteristically, EBV-transformed B cell lines are negative for the expression of T cell (CD3), NK 
cell (CD56), granulocyte (CD66b), and monocyte (CD14) surface markers, as previously reported 
[100,101]. Thereby, it would be important to use a cell viability marker to exclude dead cells, as 
well as additional surface markers specific to other leukocyte populations to confirm the purity of 
EBV-transformed B cell lines in future studies. 
In turn, another hypothesis is that those CD19– cells are transformed B cells that lost 
CD19 expression in the course of EBV-induced transformation. This seems to be supported by the 
fact that, during the phenotyping of the EBV-transformed B cell line from control subject #1 using 
fluorescein isothiocyanate (FITC)-labelled anti-human CD19 antibody, no fluorescence signal was 
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detected in spite of the successful transformation of B cells based on regular observations of the 
culture; this problem did not occur in subsequent analyses of the remaining EBV-transformed B 
cell lines wherein phycoerythrin conjugated with cyanin-7 (PE-Cy7)-labeled anti-human CD19 
antibody was used. Since the first fluorochrome is comparatively less sensitive than this latest, the 
absence of the fluorescein isothiocyanate (FITC) signal may have been potentiated by a reduced 
expression of CD19 in transformed B cells from control subject #1. In a previous report, the CD19 
expression did also appear to be down-regulated in EBV-transformed B cells in comparison with 
non-infected B cells, as evidenced by a decrease in the mean fluorescence of CD19 [102]. Another 
study concerning the phenotype of EBV-transformed B cell lines described that, although the 
majority expressed CD19, some were negative for this B cell marker, as assessed by a level of cell 
staining lower than 10% [101]. Together, these data suggest that EBV-mediated B cell 
transformation may induce an alteration of surface marker expression, namely of CD19. Thereby, 
it would be important to perform, in the future, the characterization of EBV-transformed B cell 
lines using additional B cell-specific markers to assess if their expression is more homogeneous 
than that of CD19, thus allowing the identification of all B cells within the cultures after viral 
transformation, or whether the combined expression of two surface markers (e.g. CD19 and 
CD20) would allow the recognition of a higher percentage of EBV-transformed B cells. 
 
In terms of the factors that could have conditioned the efficacy in the generation of EBV-   
-transformed B cell lines, herein it was demonstrated that the frequency of B cells within PBMCs 
used in the transformation process does not influence the B cell levels in the samples of EBV-          
-transformed B cell lines and, therefore, is not an indicator of the growth progression of virally 
infected cell clusters. Surprisingly, in this study, it was observed that the emergence of adherent 
cells in the culture was a major limiting factor of the development of EBV-transformed B cell lines. 
 
 
7.2. Phenotype of EBV-transformed B cell lines from MPS II and MPS VI patients 
 
The phenotyping of EBV-transformed B cell lines from MPS II and MPS VI patients upon 
35 days of culture revealed a predominance of double-negative memory B cells in both groups as 
well as in control subjects. When considering the frequency of each B cell phenotype in the EBV-   
-transformed B cell lines, no differences concerning the levels of naïve, double-negative memory, 
IgM memory, and switched memory B cells were found in MPS II and MPS VI patients as 
compared with control subjects or between both patient groups. 
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Prior to EBV-induced transformation, the predominant B cell subpopulation in the PBMC 
samples from the three groups corresponded to naïve B cells. Interestingly, in contrast to the EBV-   
-transformed B cell lines, the percentage of double-negative memory B cells within PBMCs was 
quite reduced in all groups. The determination of the B cell subset frequency before viral infection 
showed no alterations in peripheral blood naïve, double-negative memory, IgM memory, switched 
memory, and plasma B cells between MPS II and MPS VI patients or when comparing each patient 
group with control subjects. As expected, circulating plasma B cells were almost undetectable in 
the three groups, indicating that all individuals included in this study were at steady-state 
conditions. 
In the comparative analysis within each group of the percentage of B cell compartments 
before infection with EBV virions (day 0) and following viral transformation (day 35), a significant 
increase of double-negative memory B cells was identified in the EBV-transformed B cell lines 
from control subjects. Furthermore, a tendency toward increased levels of the double-negative 
memory B cell subpopulation after EBV-mediated transformation was clearly observed in MPS II 
and MPS VI patients. Given the large variation in the frequency of double-negative memory B cells 
in these two groups between day 0 and day 35 post-infection, the most likely explanation for the 
lacking of statistical significance is the reduced number of MPS II and MPS VI patients that were 
analyzed for these parameters. Similarly, a trend to a decrease of naïve and IgM memory B cells 
was detected in the three groups when comparing the respective percentage within PBMCs prior 
to viral infection with the samples of EBV-transformed B cell lines. On the contrary, in all groups, 
no differences were found in the switched memory B cell levels between the two time points. 
 
Taking into account that the predominant phenotype of EBV-transformed B cell lines was 
the one corresponding to the double-negative memory B cell subset, three hypotheses can be 
proposed regarding the origin of such phenotype: (i) the double-negative memory B cells, whose 
frequency on day 0 was considerably reduced, were selectively infected by EBV; (ii) IgM memory 
B cells, which presented intermediary levels before viral infection, were mostly transformed by 
EBV and, in the course of this process, lost the expression of IgM and CD27 surface markers; or 
(iii) naïve B cells, which constituted the major compartment within the B cell population on day 0, 
were preferentially infected by the virus and, as a consequence, differentiated into memory B cells 
with double-negative phenotype. 
A previous study on the susceptibility of B cell subsets to EBV-induced transformation in 
vitro reported that circulating naïve B cells were significantly more prone to infection than their 
memory counterparts [103]. However, this finding contrasts with the fact that, in latently infected 
human carriers, EBV was found exclusively in the peripheral blood compartment of memory B 
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cells, whose phenotype was characterized as IgD–Ig+CD27+ [104,105]. Some authors proposed 
that, although EBV is capable of directly infecting resting memory B cells, it specially shows the 
capacity to target naïve B cells and establish a latent infection in them, possibly owing to their 
inherently higher proliferation rate [103,104]. Subsequently, the activated naïve B cells are driven 
by the virus through a maturation stage that mimics the GC reaction and, as a consequence, the 
newly infected cells are induced to proliferate; however, they are also able to exit the cell cycle 
and become resting memory B cells, rather than terminally differentiate into antibody-secreting 
plasma B cells [103,104]. For this purpose, after infecting naïve B cells, the resulting activated, 
proliferating B blasts initially express EBNA-2 [104,106], which promotes the transcriptional 
activation of viral (e.g. LMP-1, LMP-2) and cellular genes (e.g. CD21, CD23), leading to EBV-             
-infected cell expansion [77,81]. Due to their ability to switch off EBNA-2 transcription, they can 
become GC cells which, instead of expressing such growth program, downregulate the latent 
genes and only produce EBNA-1 [104,106], a protein essential for EBV genome replication and its 
maintenance as viral episomes [77,81]; consequently, these B blasts can transit from a 
proliferating to a resting state [104,106]. Then, in order to escape from apoptosis due to absence 
of antigen-stimulatory signals and T cell-mediated positive selection, infected B cells express 
LMP-1 and LMP-2 by an EBNA-2-independent pathway [104,106]: the first mimics the function of 
CD40, a cellular B cell-activating surface molecule that interacts with CD40 ligand in helper T 
cells, which induces B cell proliferation, affinity maturation, and Ig class switching during GC 
reaction; the second acts like the genuine BCR, blocking the normal signal transduction via this 
cellular receptor to prevent EBV lytic infection [81]. As a result, both viral proteins supply the 
required rescue signals that replace antigen- and T cell-dependent activation, thus promoting the 
survival of GC cells and their differentiation into memory B cells that express solely LMP-2, which 
provides the frequent signaling through a functional BCR that is essential for prolonged survival 
[104,106]. 
Summing up, EBV has evolved to exploit the normal cellular mechanisms by which 
antigen-responsive, proliferating naïve B cells develop in vivo into resting memory B cells, 
allowing this human herpesvirus to ensure its lifetime persistency in this long-lived B cell pool 
[104,106]. Therefore, this may potentially be the pathway through which the EBV-transformed B 
cell lines produced in vitro in our work acquired a predominant phenotype of double-negative 
memory B cells. This hypothesis is in accordance with the findings that the frequency of the naïve 
B cell subpopulation considerably decreased in the course of EBV-induced transformation, at the 
same time that the percentage of the double-negative memory B cell subset substantially 
increased during the 35 days of culture of the virally infected cells. 
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8. CONCLUSION AND FUTURE PERSPECTIVES 
 
This thesis aimed to characterize the immune system in MPS II and MPS VI diseases by 
studying the frequency of the major peripheral blood leukocyte populations – T cells and their 
compartments, NK cells, B cells and their subsets, as well as monocytes. Other main purposes of 
this work were to generate EBV-transformed B cell lines from MPS II and MPS VI patients, 
evaluate the efficacy in their production, and perform their phenotyping. 
 
In the study of the various immune cell populations in MPS II and MPS VI diseases, a 
statistically significant decrease in the levels of NK cells and monocytes was uncovered in MPS VI 
patients, but not in MPS II patients, as compared with the control group. On the contrary, no 
alterations were detected in the percentage of total T cells, helper and cytotoxic T cell subsets, 
iNKT cells, iNKT cell CD4/CD8 compartments, and B cells in the two patient groups when 
comparing with control subjects. On the other hand, the analysis of the memory state of T cells 
revealed significant differences in the naïve and memory phenotypes of both helper and cytotoxic 
T cells between MPS VI patients, but not MPS II patients, and age-matched control subjects. 
In the case of other human LSDs, identical imbalances in the frequency of NK cells were 
reported in Gaucher disease [84] and Niemann-Pick disease type C1 [45], as well as a deficiency of 
monocytes in Fabry disease [40] and Gaucher disease [85] patients. Normal levels of NK cells 
were already documented in MPS II [31]. In terms of the percentage of total T cells, no alterations 
were found in Niemann-Pick disease type C1 [45] and Fabry disease [36]. Similar findings 
concerning the helper and cytotoxic T cell subpopulations were demonstrated in MPS II [31]. The 
frequency of iNKT cells was unaltered in Niemann-Pick disease type C1 [44], Fabry disease [36,40, 
41], and Gaucher disease [43]. The CD4 and CD8 status of iNKT cells was described as normal in 
Niemann-Pick disease type C1 patients [44]. In regards to the levels of B cells, no differences were 
observed in Gaucher disease [84] and Niemann-Pick disease type C1 [45]. Finally, alterations in 
the memory state of helper T cells were reported in Gaucher disease [84]. 
Altogether, the disease-specific abnormalities in some leukocyte populations that were 
identified in our work, along with similar results demonstrated in other LSDs, suggest that the 
type of macromolecular substance stored inside the lysosome or the specific causative 
mutation(s), rather than the abnormal substrate accumulation per se, play a major role in the 
triggering of particular cellular damages that potentially cause such alterations. This underlines 
the importance to assess the potential negative effects of the different storage materials and 
enzymatic defects on the normal cellular composition of the immune system in LSD patients. 
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With respect to the production of EBV-transformed B cell lines, this process was 
successfully accomplished in the two groups of MPS patients. Comparing with control subjects, 
the efficacy in the generation of EBV-transformed B cell lines from MPS II patients did not show 
substantial differences. On the other hand, a considerably higher efficacy in the production of 
EBV-transformed B cell lines was registered in the case of MPS VI patients when compared with 
control subjects and MPS II patients, as demonstrated by the larger ratio of expansion of the B cell 
population subsequent to viral transformation. The main difference observed between the two 
patient groups regarding the development of EBV-transformed B cell lines was related with the 
appearing of adherent cells, which occurred in all virally infected cell cultures from MPS II 
patients, but only in one of the MPS VI patients. Such regression of the global expansion of cell 
aggregates in the presence of adherent cells is proposed to be associated with the actions of DCs 
in the priming of both innate and adaptive EBV-specific immune responses. Either by directly 
secreting IFN cytokines [96], through activation of innate NK cells [98], or via stimulation of 
adaptive T cells [99], DCs may have been an important factor that conditioned the proliferation of 
cell clusters in the cultures from MPS II patients. On the other hand, the frequency of B cells 
within the original PBMC samples was shown herein not to be a determinant factor of the growth 
progression of EBV-infected cells and their expansion into actively proliferating EBV-transformed 
B cell lines. 
The analysis of the frequency of B cell subpopulations revealed no alterations in MPS II 
and MPS VI patients in comparison with control subjects, either before or after EBV-mediated 
transformation of B cells. The phenotypic characterization of EBV-transformed B cell lines 
demonstrated a predominance of double-negative memory B cells in both patient groups and 
similar results were observed for control subjects. However, in the samples of PBMCs used in viral 
infection, naïve B cells represented the more prevalent B cell subset in MPS II and MPS VI patients 
as well as in the control group. This discrepancy led to the hypothesis that naïve B cells were 
preferentially infected by EBV in vitro and that, during the transformation process, they 
differentiated into memory B cells with double-negative phenotype. In agreement with this theory 
is the fact that peripheral blood naïve B cells were already described to be significantly more 
susceptible to EBV infection than their memory counterparts [103], as well as the observation 
that this virus was found exclusively in the circulating memory B cell compartment in latently 
infected human carriers [104,105]. Accordingly, some authors proposed that EBV produces a 
latent infection in naïve B cells, which are driven by the virus to differentiate into resting memory 
B cells so that EBV is able to ensure its lifetime persistency in this long-lived B cell pool in vivo 
[104,106]. Hence, this may also be the mechanism exploited by EBV to establish transformed B 
cell lines in vitro. 
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Given that this work involved immunological analyses performed in human patients, 
several limitations emerged in the course of our studies. To cite a few, since MPS II and MPS VI are 
rare disorders – with an estimated prevalence in Portugal of 1.09 and 0.42 per 100,000 live births 
[13], respectively – and few Portuguese subjects are affected by these diseases, it was only 
possible to recruit a small number of patients for this work; there were also some contretemps 
regarding the reception of blood samples from these patients that delayed the overall 
experimental activities; in various cases, a small amount of peripheral blood was received from 
patients, owing to the fact that most of them were children and also because of their general poor 
health status, which limited the number of PBMCs that were isolated and used for B cell 
transformation as well as for PBMCs flow cytometry; some alterations may have not been 
identified as statistically significant comparing with control subjects due to the reduced number 
of individuals that composed each MPS patient group, especially in the study related to EBV-           
-transformed B cell lines. This problem was complicated by the fact that it is always more difficult 
to perform studies using blood samples from children and, although we have had the 
collaboration of one hospital to receive blood from pediatric MPS patients and control subjects, 
the respective ethical committee did not approve their use in the process of B cell transformation. 
Consequently, another limitation was the impossibility to include age-matched controls for the 
production and phenotyping of EBV-transformed B cell lines, as only adult volunteers from IBMC 
could participate in this work. 
 
To conclude, since the pathophysiology of LSDs remains largely unknown, we expect to 
continue analyzing MPS II and MPS VI patients in the future, including untreated affected 
individuals, to improve our understanding on the effect of ERT in the correction and/or alteration 
of the immune status in these disorders. With our study, we hope to have contributed for the 
better comprehension of these two rare diseases, namely the effects of their metabolic 
deficiencies in the normal cellular composition of the immune system. Moreover, the production 
of EBV-transformed B cell lines, which were obtained by a less invasive method compared to 
fibroblast cell lines, allowed not only to perpetuate the genetic material of these rare Portuguese 
patients, but also their potential use by the national and international scientific communities. As a 
result of this work, we have nowadays available in our laboratory four EBV-transformed B cell 
lines from MPS II patients and five from MPS VI patients, which can be used in future 
immunological, biochemical, and genetic analyses. 
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APPENDIX 
 
Composition of the solutions employed in the experimental activities 
 
PBS 10x 
For a final volume of 1000mL: 
– 80g of NaCl 
– 2g of KCl 
– 6.09g of Na2HPO4 
– 2g of KH2PO4 
– 1000mL of H2O 
Adjust pH to 7.3 
 
PBS 1x 
For a final volume of 500mL: 
– 50mL of PBS 10x 
– 450mL of H2O 
 
ACK lysing solution 
For a final volume of 500mL: 
– 4.15g of NH4Cl 
– 0.5g of KCO3 
– 500mL of H2O 
Adjust pH to 7.2 
 
Flow cytometry solution (PBS 0.2% BSA 0.1% NaN3) 
For a final volume of 100mL: 
– 0.2g of bovine serum albumin (BSA) 
– 0.1g of NaN3 
– 100mL of PBS 1x 
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Cell fixing solution (PBS 1% formaldehyde) 
For a final volume of 10mL: 
– 0.625mL of 16% formaldehyde 
– 9.375mL of PBS 1x 
 
Culture media 
– RPMI 10% iFBS 
– 50mL of iFBS (Invitrogen) 
– 5mL of non-essential amino acids (Invitrogen) 
– 5mL of kanamycin (Invitrogen) 
– 5mL of sodium pyruvate (Invitrogen) 
– 500mL of RPMI-1640 medium, GlutaMAX™-I supplement (Gibco®) 
 
– RPMI 20% iFBS 
– 100mL of iFBS (Invitrogen) 
– 500mL of RPMI 1640 medium, GlutaMAX™-I supplement (Gibco®) 
 
Freezing medium (iFBS 10% DMSO) 
For a final volume of 55mL: 
– 5mL of dimethyl sulfoxide (DMSO) 
– 50mL of iFBS 
 
